Efficient Chemoenzymatic Synthesis of an N-glycan Isomer Library

Lei Li,^{1,#} Yunpeng Liu,^{1,#} Cheng Ma,^{1,#} Jingyao Qu,¹ Angie D. Calderon,¹ Baolin Wu,² Na Wei,¹ Xuan Wang,¹ Yuxi Guo,¹ Zhongying Xiao,¹ Jing Song,¹ Go Sugiarto,³ Yanhong Li,³ Hai Yu,³ Xi Chen,³ and Peng George Wang^{*,1}

¹Department of Chemistry and Center of Diagnostics & Therapeutics, Georgia State University, 50 Decatur St SE, Atlanta, GA 30303

²Chemily, LLC, 58 Edgewood Ave NE, Atlanta, GA 30303

³Department of Chemistry, University of California, Davis, One Shields Avenue, Davis, CA 95616

Supporting Information

Table of Contents

I. Materials and enzymes	S2
II. General methods for enzyme treatment	S2
III. General methods for HPLC analysis and purification of N-glycans	S7
IV. Groups of synthesized N-glycan isomers	S9
V. General methods for mass spectrum analysis	S10
VI. Chemical synthesis	S11
VII. HPLC profiles, MS and NMR data of purified N-glycans	S29
VIII. NMR spectra of purified N-glycans	S104
IX. References	S132

I. Materials and enzymes

Neu5Gc and CTP were purchased from Carbosynth Limited. β 1,4-galactosyltransferase from bovine milk (B4GALT1) was purchased from Sigma. Thermosensitive Alkaline Phosphatase from shrimp (FastAP) was purchased from Thermo Scientific. Recombinant human FUT8 was purchased from Fisher Scientific. Other enzymes including double mutant E271F/R313Y from *Pasteurella multocida* α 2,3-sialyltransferase 1 (PmST1m)¹, α 2,6-sialyltransferase from *Photobacterium damslae* (Pd2,6ST)², C-terminal 66 amino acids truncated *Helicobacter pylori* α 1,3-fucosyltransferase (Hp α 1,3FT)³, CMP-sialic acid synthetase from *N. meningitidis* (NmCSS)⁴ were expressed and purified as previously described. Enzymes were then desalted against 50 mM Tris-HCl, 100 mM NaCl, and 50% glycerol, and stored at -20 °C for long term use. Sugar nucleotides uridine 5'-diphospho-galactose (UDP-Gal)⁵, cytidine 5'-monophospho-N-acetylneuraminic acid (CMP-Neu5Ac)⁴ and guanoside 5'-diphospho-L-fucose (GDP-Fuc)⁶ were prepared as described previously.

II. General methods for enzyme treatment

A) β1,4-galactosylation catalyzed by B4GALT1



Figure S1. HILIC-ELSD analysis of **N001** glycans yielded from P2. Waters XBridge BEH amide column was used (130 Å, 5 μ m, 4.6 mm × 250 mm) under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 1 mL/min; B%: 70-50% within 50 min).

Reactions contain 50 mM Tris-HCl (pH 8.0), 4 mM of acceptor glycans, 8 mM of UDP-Gal, 5 mM of MnCl₂, and varying amounts of B4GALT1. FastAP (1 U/200 μ L) was also added to digest the reaction byproduct UDP to drive reaction forward. Reactions incubated at 37 °C for 2-12 h, and monitored by HILIC-ELSD (amide column, 4.6 mm × 250 mm under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25 min)). After over 90% acceptor converted, the reaction was quenched by been put in -80 °C for 30 min, followed concentration by lyophilization. HPLC-A_{210nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 μ m, 10 mm × 250 mm). The running conditions are solvent A: 100 mM ammonium formate (for glycans with Sia residues) or water (for glycans without Sia residues), pH 3.4; solvent B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25.50% within 25 min).



Figure S2. HILIC-_{210nm} purification of **N001** yielded from P2. Waters XBridge BEH amide column was used (130 Å, 5 μ m, 10 mm × 250 mm) under a gradient condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 4 mL/min; B%: 70-50% within 50 min). The peak corresponding to **N001** was pooled and lyophilized twice to remove ammonium formate.

B) α 2,3-sialylation catalyzed by PmST1m

Reactions contain 100 mM Tris-HCl (pH 8.0), 4 mM of acceptor glycans, 8 mM of CMP-Neu5Ac, and of PmST1m (5 μ g/mL). Reactions were incubated at 37 °C for 30 min and quenched by been put in -80 °C for 30 min, followed concentration by lyophilization. HPLC-A_{210nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 μ m, 10 mm × 250 mm). The running conditions are solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25 min. For the synthesis of Neu5Gc containing glycans, CMP-Neu5Ac was simply substituted by reagents for CMP-Neu5Gc synthesis (8 mM Neu5Ac, 8 mM CTP, 5 mM MgCl₂, and excessive amounts of NmCSS).

C) α 2,6-sialylation catalyzed by Pd2,6ST

Reactions contain 100 mM Tris-HCl (pH 8.0), 4 mM of acceptor glycans, 8 mM of CMP-Neu5Ac, and varying amounts of Pd2,6ST. 1 U/200 μ L) was also added to digest the reaction byproduct UDP to drive reaction forward. Reactions incubated at 37 °C for 2-12 h, and monitored by HILIC-ELSD (amide column, 4.6 mm × 250 mm under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25 min). HPLC-A_{210nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 μ m, 10 mm × 250 mm). The running conditions are solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25 min. **Supplementary Figure 3** shows that only MS detectable product was found when Pd26ST was used to synthesized Neu5Ac6Le^X-OBn (a unnatural glycan). For the synthesis of Neu5Gc containing glycans, CMP-Neu5Ac was simply substituted by reagents for CMP-Neu5Gc synthesis (8 mM Neu5Ac, 8 mM CTP, 5 mM MgCl₂, and excessive amounts of NmCSS).



Figure S3. MS analysis of Pd2,6ST catalyzed formation of Neu5Ac6Le^X-OBn.

D) α 1,3-fucosylation catalyzed by Hp α 1,3FT

Reactions contain 50 mM Tris-HCl (pH 8.0), 4 mM of acceptor glycans, 8 mM of GDP-Fuc, 5 mM of MnCl₂, and varying amounts of Hp α 1,3FT. FastAP (1 U/200 µL) was also added to digest the reaction byproduct GDP to drive reaction forward. Reactions incubated at 37 °C for 4-24 h, and monitored by HILIC-ELSD (amide column, 4.6 mm × 250 mm under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25 min)). After over 90% acceptor converted, the reaction was quenched by been put in -80 °C for 30 min, followed concentration by lyophilization. HPLC-A_{210nm} was then used to purify target glycans using a semi-preparative amide column (130 Å, 5 µm, 10 mm × 250 mm). The running conditions are solvent A: 100 mM ammonium formate (for glycans with Sia residues) or water (for glycans without Sia residues), pH 3.4; solvent B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25 min).



Figure S4. HILIC-ELSD analysis of Hpa1,3FT catalyzed fucosylation of N012.



Figure S5. Synthetic scheme of glycans N2XX and N144 by enzymatic extension. a) B4GALT1; b) 30% ammonium hydroxide treatment for 6 h; c) PmST1m; d) Pd2,6ST; e) Hp α 1,3FT. Each N-glycan was purified into 98% pure by HPLC with a semi-preparative amide column (10 × 250 mm).

D) Substrate specificity study of Hpa1,3FT towards various acceptors

Reactions contain 50 mM Tris-HCl (pH 8.0), 2 mM of acceptor glycans, 4 mM of GDP-Fuc, 5 mM of MnCl₂, and 1 μ g of Hp α 1,3FT. FastAP (1 U/200 μ L) was also added to digest the reaction byproduct GDP to drive reaction forward. Reactions incubated at 37 °C for 1 h, and analyzed by HILIC-ELSD (or UV210) (amide column, 4.6 mm × 250 mm under a gradient running condition (solvent A: 100 mM ammonium formate, pH 3.4; solvent B: acetonitrile; flow rate: 1 mL/min; B%: 65-50% within 25 min).

It was found that Hp α 1,3FT has a strict requirement of terminal glycans (e.g., requires LacNAc or Sia3LacNAc for activity), but a very relaxed requirement of glycans linked to the reducing end of GlcNAc (e.g., it showed similar activity towards LacNAc-OBn, **N011**, **N021**, **N211**, etc.). The enzyme showed reduced activity towards N125 and N225 (highlighted), possibly due to the α 1,3-fucose located on the other antennary of N-glycans. Also, as expected core-fucosylation did not affect the activity of Hp α 1,3FT (N211, 82.4%; N6211, 78.9%).

Substrate	Terminal glycan of substrate	Product	Yield (%)
GlcNAc-OBn			ND
N010			ND
N020	GlcNAc		ND
N040			ND
N110	1		ND
N210			ND
LacNAc-OBn		Le ^x -OBn	100
N011		N014	90.6
N021	1	N024	100
N031		N034	93.8
N041		N044	97.6
N051		N054	95.4
N111	LacNAC	N114	88.9
N123		N244	86.7
N125	1	N155	41.0
N211		N214	82.4
N223		N144	89.1
N225		N255	57.4
N6211		N6214	78.9
N012G	Neu5Gc3LacNAc	N015G	34.2
S3LacNAc-OBn		SLe ^x -OBn	34.2
N012		N015	30.5
N022		N025	40.2
N032	New 5 A e21 eeNIA e	N035	38.6
N042	NeuSACSLacINAC	N045	40.0
N052		N055	33.7
N112		N115	26.9
N212	7	N215	23.0
S6LacNAc-OBn		S6Le ^X -OBn	ND
N013	7		ND
N023	Nou5A of LooNA o		ND
N033	INCUSACOLICINAC		ND
N043	-		ND
N053			ND

Table S1 Substrate specificity of Hpa1,3FT towards various acceptors

III. General methods for HPLC analysis and purification of N-glycans

A) General methods for HILIC-ELSD analysis of N-glycans

<u>Column</u>: Waters XBridge BEH amide column, 130 Å, 5 µm, 4.6 mm × 250 mm Solvent A: 100 mM ammonium formate, pH 3.4 Solvent B: Acetonitrile Temperature: 40 °C Gradient elution: Flow rate Time B% 0 65 1 25 50 1 26 0 0.5 27 0.5 0 28 65 1 30 65 1 Monitor: Evaporative light scattering detector, 60 °C (Shimadzu ELSD-LTII)

B) General methods for HILIC-UV210 purification of N-glycans

Column: Waters XBr	idge BEH amid	e column, 130	Å, 5 μ m, 10 mm × 250 mm
Solvent A: Water or 1	00 mM ammor	nium formate, p	oH 3.4
Solvent B: Acetonitri	le		
Temperature: 40 °C			
Gradient elution:	Time	B%	Flow rate
	0	65	4
	25	50	4
	26	0	2
	27	0	2

65

65

4

4

Monitor: A_{210nm}

C) Test of different solvents for HILIC separation of N-glycans

28

30

Column: Waters XBridge BEH amide column, 130 Å, 5 µm, 4.6 mm × 250 mm Solvent A1: 100 mM Ammonium Formate, pH 3.4 Solvent A2: Water Solvent A3: 10 mM Formic Acid Solvent B: Acetonitrile Temperature: 40 °C Gradient elution: Time B% Flow rate 0 70 1 50 50 1 52 0.5 0

54	0	0.5
56	70	1
60	70	1

Monitor: Evaporative light scattering detector, 60 °C (Shimadzu ELSD-LTII)



Figure S6. Separation of N-glycans using different solvent combinations. Results showed that 100 mM of ammonium formate gave best separation of all tested N-glycans (B), and solvent does not matters then separating non-sialylated N-glycans (C, D, F). In addition, the use of water yielded rapid elution of sialylated N-glycans (B, C).

IV. Groups of synthesized N-glycan isomers



Figure S7. Groups of synthesized N-glycan isomers. Each group contains 2 to 6 distinct structures.

V. General methods for mass spectrum analysis

A) ESI-MS and MS² analysis of N-glycans

In this study, HPLC-MS experiments were performed on an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher) equipped with EASY-spray source and nano-LC UltiMate 3000 high performance liquid chromatography system (Thermo Fisher). Samples were transmitted into MS with a silica column. LTQ-Orbitrap Elite mass spectrometer was operated in the data-dependent mode. A full-scan survey MS experiment (m/z range from 375 to 1600; automatic gain control target, 1,000,000 ions; resolution at 400 m/z, 240,000; maximum ion accumulation time, 200 ms) was acquired by the Orbitrap mass spectrometer. CID fragmentation ion spectra were acquired in ion-trap spectrometer (automatic gain control target, 10,000 ions; maximum ion accumulation time, 100 ms), and Normal Collision Energy (NCE) of CID is set to 35.



Figure S8. MS2 analysis of 4 N-glycan isomers (N002, N003, N133 and N233).

B) MALDI-MS running conditions

MALDI-MS experiments were performed on UltrafleXtreme MALDI TOF/TOF Mass Spectrometer (Bruker). Scan range of MS^1 was according to the molecular weight of N-glycans, and reflector mode was used for N-glycan analysis. Mass spectra were obtained in both positive and negative extraction mode with the following voltage settings: ion source 1 (19.0 kV), ion source 2 (15.9 kV), and lens (9.3 kV). The reflector voltage was set to 20 kV. The laser was pulsed at 7 Hz and the pulsed ion extraction time was set to 400 ns. The laser power was kept in the 25–40% range.

VI. Chemical Synthesis

Materials: All chemicals were purchased as reagent grade and used without further purification. Anhydrous dichloromethane (CH₂Cl₂), acetonitrile (CH₃CN), tetrahydrofuran (THF), N,Ndimethyl formamide (DMF), toluene, and methanol (MeOH) were purchased from a commercial source without further distillation. Pulverized Molecular Sieves MS-4 Å (Aldrich) for glycosylation was activated by heating at 350 °C for 3 h. Reactions were monitored by analytical thin-layer chromatography (TLC) in EM silica gel 60 F254 plates and visualized under UV (254 nm) and/or by staining with acidic ceric ammonium molybdate or *p*-anisadehyde. Flash chromatography was performed on silica gel (Merck) of 40-63µm particle size and P2 gel (Biorad). ¹H NMR spectra were recorded on a Bruker AVANCE 400 (400 MHz), and Bruker AVANCE 500 (500 MHz) spectrometer at 25 °C. All ¹H Chemical shifts (in ppm) were assigned according to CDCl₃ (δ = 7.24 ppm) and D₂O (δ = 4.79 ppm). ¹³C NMR spectra were obtained with Bruker AVANCE 600 spectrometer and calibrated with CDCl₃ (δ = 77.00 ppm). Coupling constants (J) are reported in hertz (Hz). Splitting patterns are described using the following abbreviations: s, singlet; brs, broad singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublet; m, multiplet. 1H NMR spectra are reported in the following order: chemical shift, multiplicity, coupling constant(s), and number(s) of protons. All NMR signals were assigned on the basis of ¹H NMR, COSY, HSQC, HMQC, and ¹³C NMR experiments. High resolution MALDA mass spectra were recorded on a Bruker Ultraflextreme spectrometer.

General Procedures.

<u>A) Glycosylation procedure:</u> A mixture of donor (1.3 mmol), acceptor (1 mmol) and 4 Å molecular sieves in dry Et₂O (or CH₂Cl₂) was stirred at room temperature under argon for 2 h. NIS (1.5 mmol) and AgOTf (0.2 mmol) were added at 0 °C. The reaction mixture was stirred at 0 °C for 0.5 h before it was quenched with a few drops of triethylamine. The resulting mixture was filtered. The filtrate was diluted with CH_2Cl_2 and washed with 5% $Na_2S_2O_3$, aqueous NaHCO₃, brine, dried over Na_2SO_4 , and concentrated. The residue was purified on a silica gel column to produce the product.

<u>B)</u> Benzylidene opening procedure: A mixture of oligosaccharide (1 mmol) and 4 Å molecular sieves in dry CH_2Cl_2 was stirred at room temperature under argon for 2 h. PhBCl₂ (2 mmol) and Et₃SiH (2 mmol) were added at -78 °C. The reaction mixture was stirred at -78 °C for 3 h before it was quenched with a few drops of triethylamine. The resulting mixture was filtered. The filtrate was diluted with CH_2Cl_2 and washed with aqueous NaHCO₃, brine, dried over Na₂SO₄, and concentrated. The residue was purified on a silica gel column to afford the product.

<u>C)</u> Transformation of N-Phth to NHAc procedure: A mixture of N-Phth protected oligosaccharide was dissolved in *n*BuOH at room temperature, followed by addition of ethylenediamine (*n*BuOH: ethylenediamine = 2:1). After being stirred at 90 °C for 12 h, the mixture was evaporated *in vacuo* to give a residue for the next step without further purification. To a solution of the residue in pyridine was added Ac₂O. After being stirred at room temperature for 12 h, the solution was diluted with EtOAc and washed with aqueous HCl (1 M), saturated aqueous NaHCO₃, and brine solution. The organic layer was dried over Na₂SO₄, filtered, and evaporated *in vacuo* to give a residue, which was purified by silica gel column chromatography to give N-NHAc compound.

<u>D) Deacetylation procedure:</u> Ac-protected oligosaccharide was dissolved in MeOH, and NaOMe in MeOH was added until pH was 10. After stirring at room temperature for 2 h, the solution was neutralized with ion-exchange resin (H+), and then filtered. The residue was purified on a silica gel column to afford the desired deacetylated product

<u>E) Global deprotection procdure:</u> $Pd(OH)_2$ on carbon was added to a solution of protected oligosaccharide in MeOH/H₂O (10/1). The mixture was stirred under 1 atmosphere of hydrogen. After being stirred for 24 h, the mixture was filtered through a PTFE syringe filter and concentrated in *vacuo*. The residue was purified by Bio-Gel P-2 (BIO-RAD) column chromatography using water as eluent. The product was then lyophilized to get target compound, as white powder.

Ethanethiol 3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tri-benzyl- α -D-Mannopyranoside (4):



Compound 3^7 (1 g, 1.1 mmol) was dissolved in MeOH, and NaOMe in MeOH was added until pH was 10. After stirring at room temperature for 2 h, the solution was neutralized with ionexchange resin (H⁺), and then filtered. The residue was dried under *vacuo* without further purification for next step, and then the residue was dissolved in dry DMF (10 mL). NaH (238 mg, 5.94 mmol), Bu₄NI (221 mg, 0.6 mmol), followed by BnBr (588 µL, 4.95 mmol) were added at 0 °C, the reaction mixture was stirred under argon for 4 h. The solvent was evaporated, and the residue was diluted with ethyl acetate and washed with water and a brine solution. After dried over Na₂SO₄, the organic layer was evaporated. The residue was purified on a silica gel column (Hexanes: EtOAc = 5:1) to afford the desired product 4 (929 mg, 80% over two steps) as colorless oil. $[\alpha]_D^{20}$ -1.68 (c 1, CH₂Cl₂);¹H NMR (CDCl₃, 400 MHz): δ 7.56-7.57 (m, 2 H), 7.30-7.40 (m, 23 H), 7.19-7.21 (m, 2 H), 7.13-7.15 (m, 2 H), 7.07-7.08 (m, 2 H), 6.89-6.95 (m, 3 H), 5.36 (d, J = 8.1 Hz, 1 H), 5.05 (s, 1 H), 4.82-4.94 (m, 4 H), 4.70 (d, J = 11.5 Hz, 1 H), 4.62 (d, J= 14.1 Hz, 1 H), 4.63 (d, J = 16.2 Hz, 1 H), 4.59 (d, J = 12.5 Hz, 1 H), 4.56 (d, J = 13.1 Hz, 1 H), 4.53 (d, J = 12.1 Hz, 1 H), 4.37-4.45 (m, 3 H), 4.21 (brs, 1 H), 4.05 (brs, 2 H), 3.92 (t, J = 10.6Hz, 1 H), 3.77-3.79 (m, 2 H), 3.55 (t, J = 5.2 Hz, 1 H), 3.43 (d, J = 10.6 Hz, 1 H), 3.01 (d, J = 10.6 Hz, 1 H) 10.7. 6.8 Hz, 1 H), 2.37-2.53 (m, 2 H), 1.18 (t, J = 7.4 Hz, 3 H); ¹³C NMR (CDCl₃, 100 MHz): δ163.5, 138.5 (2 C), 138.0 (2 C), 133.6, 131.8, 128.6, 128.5, 128.4 (2 C), 128.3, 128.2 (2 C), 128.1, 128.0 (2 C), 127.9, 127.8, 127.7, 127.5, 127.4 (3 C), 123.1, 96.6, 92.3, 80.9, 79.7, 79.2, 78.1, 75.5, 75.2, 75.1, 75.0, 74.9, 74.8, 73.7, 72.8, 71.9, 70.9, 69.9, 69.2, 55.8, 25.3, 14.7. MALDI-MS: [M+Na]+ C₆₄H₆₅NO₁₁SNa calcd for 1078.4176, found 1078.4147

Ethanethiol 2,3,4,6-O-tetra-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 3)$ -[2,3,4,6-O-tetra-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 6)$]-2,4-O-di-benzyl- α -D-Mannopyranoside (5):



To the solution of compound 5-1⁸ (2 g, 1.32 mmol) in THF (20 mL) was added TBAF (1.98 mL, 1.98 mmol) at room temperature. After being stirred for 2 h, the mixture was concentrated, purified by flash chromatography to give the compound 5-2. The residue was dissolved in dry DMF (20 mL). NaH (95 mg, 2.38 mmol), Bu₄NI (74 mg, 0.2 mmol), followed by BnBr (235 μL, 1.98 mmol) were added at 0 °C, and the reaction mixture was stirred under argon for 4 h. The solvent was evaporated, and the residue was diluted with ethyl acetate and washed with water and a brine solution. After dried over Na_2SO_4 , the organic layer was evaporated. The residue was purified on a silica gel column (Hexanes: EtOAc = 9:1) to afford the desired product 5 (1.63 g, 85% over two steps) as colorless oil. $[\alpha]_D^{20}$ -6.68 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.26-7.41 (m, 46 H), 7.19-7.22 (m, 4 H), 5.38 (d, J = 1.5 Hz, 1 H, H-1), 5.34 (d, J = 1.5 Hz, 1 H, H-1), 5.11 (d, J = 1.1 Hz, 1 H, H-1), 4.93 (d, J = 11.0 Hz, 1 H, PhCH₂-), 4.88 (d, J = 10.6 Hz, 1 H, PhCH₂-), 4.68-4.73 (m, 5 H), 4.65-4.67 (m, 1 H), 4.59-4.64 (m, 3 H), 4.54-4.58 (m, 2 H), 4.51-4.53 (m, 2 H), 4.47-4.50 (m, 2 H), 4.33-4.35 (m, 3 H), 4.04-4.15 (m, 4 H), 3.81-3.97 (m, 9 H), 3.73-3.77 (m, 4 H), 2.58-2.65 (m, 1 H, SCH₂CH₃), 2.47-2.56 (m, 1 H, SCH₂CH₃), 1.23 (t, J =7.4 Hz, 3 H, SCH₂CH₃); ¹³C NMR (CDCl₃, 100 MHz): δ139.0, 138.8 (2 C), 138.7 (3 C), 138.5 (2 C), 137.9 (2 C), 128.5, 128.4 (4 C), 128.3 (3 C), 128.2 (2 C), 128.1, 127.9, 127.8 (5 C), 127.7, 127.6 (4 C), 127.4 (2 C), 127.2, 127.1, 100.0, 97.6, 81.1, 80.4, 80.3, 80.0, 77.3, 75.9, 75.5, 75.3, 75.1, 75.0, 74.8, 74.7, 73.4, 73.3, 73.1, 72.7, 72.5, 72.1, 72.0, 71.8, 71.7, 71.2, 71.1, 69.2, 66.5, 25.3, 15.0; MALDI-MS: [M+Na]+ C₉₀H₉₆O₁₅SNa calcd for 1471.6368, found 1471.6454

Benzyl 3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl-(1 \rightarrow 2)-3,4,6-O-tribenzyl- α -Mannopyranosyl-(1 \rightarrow 3)-2-O-benzyl-4,6-O-benzylidene- β -D-Mannopyranosyl-(1 \rightarrow 4)-3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl-(1 \rightarrow 4)-3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranoside (6):



Compound **1** (800 mg, 0.58 mmol) was glycosylated with **4** (789 mg, 0.75 mmol) by following general procedure **A** to get the desired compound **6** (1.48 g, 93%) as colorless oil. $[\alpha]_D^{20}$ 18.8 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.90-7.92 (m, 1 H), 7.57-7.77 (m, 11 H), 6.90-7.50 (m, 62 H), 6.77-6.83 (m, 3 H), 5.36 (s, 1 H, benzylidene), 5.32 (d, *J* = 7.6 Hz, H-1), 5.08 (s, 1 H, Man H-1), 5.01 (d, *J* = 8.2 Hz, 1 H, H-1), 4.83-4.93 (m, 6 H), 4.73-4.77 (m, 4 H), 4.60-4.67 (m, 2 H), 4.51-4.58 (m, 5 H), 4.38-4.49 (m, 7 H), 4.16-4.32 (m, 9 H), 4.03-4.10 (m, 4 H), 3.93-3.96 (m, 1 H), 3.82-3.88 (m, 2 H), 3.55-3.68 (m, 7 H), 3.35-3.51 (m, 7 H), 3.28 (dd, *J* = 10.8, 2.0 Hz, 1 H), 3.17-3.20 (m, 1 H); ¹³C NMR (CDCl₃, 100 MHz): δ 177.5, 167.7, 138.9, 138.8 (2 C), 138.7,

138.5, 138.4 (3 C), 138.3, 138.1, 138.0, 137.6, 137.2, 133.5, 132.0, 131.7, 129.0, 128.4 (2 C), 128.3, 128.2 (3 C), 128.1 (2 C), 127.9 (2 C), 127.8, 127.7, 127.6 (2 C), 127.5 (2 C), 127.4, 126.9 (2 C), 126.8, 123.2, 102.1, 100.9, 97.5, 97.2, 97.1, 95.5, 79.7, 79.0, 78.8, 78.3, 78.2, 77.6, 77.3, 76.2, 76.0, 75.2, 74.9, 74.6, 74.5, 74.4, 74.3, 74.1, 73.2, 73.1, 72.9, 72.7, 72.1, 71.2, 70.6, 70.2, 69.1, 68.6, 68.2, 67.7, 66.5, 56.6, 55.8, 55.7; MALDI-MS: [M+Na]+ C₁₄₅H₁₃₇N₃O₂₉Na calcd for 2406.9235, found 2406.9355.

Benzyl 3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tri-benzyl- α -Mannopyranosyl- $(1\rightarrow 3)$ -2,4-O-di-benzyl- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranoside (7):



Compound 6 (800 mg, 0.335 mmol) was selectively opened the benzylidene ring by following general procedure **B** to get the desired title compound 7 (768 mg, 96%) as white foam. $[\alpha]_D^{20}$ -3.5 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ7.67-7.75 (m, 6 H), 7.50-7.58 (m, 4 H), 7.35-7.44 (m, 15 H), 7.25-7.35 (m, 18 H), 7.15-7.25 (m, 11 H), 6.95-7.10 (m, 12 H), 6.85-6.95 (m, 8 H), 6.75-6.82 (m, 3 H), 5.28 (d, J = 7.3 Hz, 1 H), 5.07 (d, J = 7.7 Hz, 1 H), 4.98-5.00 (m, 2 H), 4.86-4.94 (m, 3 H), 4.78-4.83 (m, 3 H), 4.69-4.74 (m, 3 H), 4.60-4.66 (m, 3 H), 4.56-4.63 (m, 2 H), 4.54-4.56 (m, 3 H), 4.49-4.52 (m, 3 H), 4.44-4.47 (m, 3 H), 4.41-4.43 (m, 1 H), 4.37-4.39 (m, 2 H), 4.33-4.35 (m, 1 H), 4.13-4.30 (m, 10 H), 3.94-4.07 (m, 4 H), 3.84-3.86 (m, 1 H), 3.68-3.73 (m, 2 H), 3.63-3.67 (m, 1 H), 3.37-3.63 (m, 2 H), 3.50-3.56 (m, 4 H), 3.40-3.47 (m, 3 H), 3.32-3.40 (m, 3 H), 3.25-3.30 (m, 2 H), 3.15-3.17 (m, 1 H); ¹³C NMR (CDCl₃, 100 MHz): δ177.9, 167.8, 138.9 (2 C), 138.8, 138.6, 138.5 (2 C), 138.4 (2 C), 138.3, 138.2, 138.0, 137.3, 133.6, 132.0, 131.8, 129.0, 128.7, 128.5 (2 C), 128.4, 128.3 (2 C), 128.2 (2 C), 128.1 (2 C), 128.0, 127.9 (2 C), 127.8, 127.7 (2 C), 127.6 (2 C), 127.5 (3 C), 127.2 (2 C), 127.0, 126.8, 123.2, 100.6, 98.8, 97.4, 97.3, 96.2, 80.8, 79.7, 79.0, 78.4, 78.1, 77.6, 76.9, 76.2, 75.4, 74.8, 74.7 (2 C), 74.5, 74.0, 73.5, 73.2, 73.0, 72.9, 72.6, 70.8, 70.6, 69.2, 68.3, 67.7, 61.9, 60.5, 56.6, 55.9, 55.8, 53.7; MALDI-MS: [M+Na]+ C₁₄₅H₁₃₉N₃O₂₉Na calcd for 2408.9392, found 2408.9255

Benzyl 3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tribenzyl- α -D-Mannopyranosyl- $(1\rightarrow 3)$ -[2,3,4,6-O-tetra-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 3)$ -[2,3,4,6-O-tetra-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 6)$]-O-2,4-O-di-benzyl- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranoside (8):



Compound 7 (300 mg, 0.126 mmol) was glycosylated with 5 (237 mg, 0.164 mmol) by following general procedure A to get the desired title compound 8 (404 mg, 85%) as colorless oil. $[\alpha]_{D}^{20}$ 20.9 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.78-7.79 (m, 1 H), 7.62-7.68 (m, 4 H), 7.54-7.56 (m, 3 H), 7.36-7.41 (m, 8 H), 7.01-7.39 (m, 100 H), 6.92-6.95 (m, 3 H), 6.85-6.87 (m, 2 H), 6.78-6.79 (m, 3 H), 6.65-6.67 (m, 3 H), 5.35 (s, 1 H), 5.23-5.25 (m, 1 H), 5.11 (d, J = 7.8Hz, 1 H), 5.03-5.04 (m, 2 H), 4.96-5.00 (m, 2 H), 4.78-4.93 (m, 8 H), 4.73-4.76 (m, 2 H), 4.70-4.71 (m, 2 H), 4.67-4.68 (m, 2 H), 4.63-4.65 (m, 2 H), 4.58-4.61 (m, 3 H), 4.41-4.56 (m, 18 H), 4.37-4.39 (m, 3 H), 4.32-4.34 (m, 2 H), 4.30-4.31 (m, 3 H), 4.24-4.27 (m, 4 H), 4.17-4.22 (m, 4 H), 4.12-4.16 (m, 4 H), 4.01-4.11 (m, 7 H), 3.95-3.98 (m, 2 H), 3.75-3.92 (m, 14 H), 3.68-3.71 (m, 6 H), 3.63-3.65 (m, 2 H), 3.48-3.59 (m, 7 H), 3.30-3.45 (m, 6 H), 3.12-3.14 (m, 1 H), 2.90-2.93 (m, 1 H), 2.74-2.78 (m, 2 H); ¹³C NMR (CDCl₃, 100 MHz): δ173.8, 171.2, 171.0, 170.6, 170.5, 168.6, 139.0, 138.9, 138.8 (3 C), 138.7 (2 C), 138.6, 138.5, 138.4, 138.3 (2 C), 138.2 (3 C), 137.9, 137.8, 128.9, 128.7, 128.6 (2 C), 128.5, 128.4 (2 C), 128.3, 128.2, 128.1 (2 C), 128.0 (2 C), 127.9 (2 C), 127.8 (3 C), 127.6 (2 C), 127.5 (3 C), 127.4 (2 C), 127.3, 127.2, 127.1, 126.5, 101.8, 100.1, 100.0, 99.9, 99.6, 98.4, 98.3, 98.0, 81.2, 80.3, 80.2, 79.7, 78.9, 78.7, 78.5, 78.1, 77.5, 77.4, 75.9, 75.1, 75.0, 74.6, 74.5, 74.4, 73.5, 73.4 (2 C), 73.3, 73.2, 72.6, 72.4, 72.2, 72.0, 71.6, 71.0, 70.5, 70.2, 70.0, 69.8, 69.6, 69.3, 69.2, 68.5, 66.6, 66.1, 60.4, 57.8, 54.8, 53.9, 50.3; MALDI-MS: [M+Na]+ C₂₃₃H₂₂₉N₃O₄₄Na calcd for 3795.5672, found 3795.5482

 $\label{eq:acetamido-b-D-glucopyranosyl-(1 \rightarrow 2)-\alpha-D-Mannopyranosyl-(1 \rightarrow 3)-[\alpha-D-Mannopyranosyl-(1 \rightarrow 3)-[\alpha-D-Mannopyranosyl-(1 \rightarrow 6)]-O-\alpha-D-Mannopyranosyl-(1 \rightarrow 6)]-O-\beta-D-Mannopyranosyl-(1 \rightarrow 4)-2-deoxy-acetamido-\beta-D-glucopyranosyl-(1 \rightarrow 4)-2-deoxy-acetamido-b-glucopyranosyl-(1 \rightarrow 4)-2-deoxy-acetamido-b-glucopyranosyl-(1 \rightarrow 4)-2-deoxy-acetamido-b-glucopyranosyl-(1 \rightarrow 4)-2-deoxy-acetami$



Following the general procedure **C**, and **E**, compound **8** (150 mg, 0.04 mmol) yielded the compound **N010** (35 mg, 63% over three steps). $[\alpha]_D^{20}$ 10.1 (c 0.5, H₂O); ¹H NMR (D₂O, 500 MHz): δ 5.22 (s, 1 H, Man5 H-1), 5.17 (d, J = 2.5 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.09 (s, 1 H, Man2 H-1), 4.92 (s, 1 H, Man3 H-1), 4.87 (s, 1 H, Man4 H-1), 4.77 (s, 1 H, Man β H-1), 4.68 (d, J = 7.7 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.60 (d, J = 7.7 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.58 (d, J = 7.7 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.54 (d, J = 8.4 Hz, 1 H,

GlcNAc-3 H-1), 4.23 (d, J = 2.4 Hz, 1 H), 4.19 (d, J = 1.7 Hz, 1 H), 4.02-4.04 (m, 1 H), 3.83-3.96 (m, 15 H), 3.58-3.82 (m, 26 H), 3.47-3.55 (m, 2 H), 3.41-3.44 (m, 2 H), 2.06 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.02 (s, 3 H, Ac); ¹³C NMR (D₂O, 125 MHz): δ 174.7, 174.5, 174.4, 101.2 ($J_{C, H}$ = 174.8, 167.3 Hz, 2 C, Man5 C-1, GlcNAc-2 C-1), 100.3 ($J_{C, H}$ = 163.6 Hz, Man β C-1), 99.5 ($J_{C, H}$ = 174.3, 173.1, 165.2 Hz, 3 C, Man2 C-1, Man4 C-1, GlcNAc-3 C-1), 99.1 ($J_{C, H}$ = 176.2 Hz, Man3 C-1), 94.7 (GlcNAc-1 C-1 of β anomer), 90.3 (GlcNAc-1 C-1 of α anomer), 80.4, 79.6, 79.3, 79.1, 76.3, 75.7, 74.5, 74.3, 73.7, 73.5, 73.2, 72.7, 72.4, 71.8, 70.7, 70.5, 70.1, 70.0, 69.9, 69.6, 69.3, 69.1, 67.2, 66.6, 66.4, 66.3, 65.5, 65.3, 61.6, 60.9, 60.8, 60.6, 60.0, 59.9, 56.0, 55.2, 54.9, 53.5, 22.2, 22.1, 21.8; ESI-MS: [M+H]+ C₅₄H₉₂N₃O₄₁ calcd for 1438.5206, found 1438.5187

2-dexoy-acetamido- β -D-glucopyranosyl- $(1\rightarrow 2)-\alpha$ -Mannopyranosyl- $(1\rightarrow 3)-\beta$ -D-Mannopyranosyl- $(1\rightarrow 4)$ -2-deoxy-acetamido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -2-deoxy-acetamido- β -D-glucopyranoside (N020):



Following the general procedure **C** and **E**, compound **6** (150 mg, 0.063 mmol) yielded the compound **N020** (40 mg, 67% over three steps). $[α]_D^{20}$ 1.8 (c 0.5, H₂O); ¹H NMR (D₂O, 500 MHz): δ 5.18 (d, J = 2.0 Hz, 0.54 H, GlcNAc-1 H-1 of α anomer), 5.11 (s, 1 H, Man2 H-1), 4.77 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.9 Hz, 0.46 H, GlcNAc-1 H-1 of β anomer), 4.59 (d, J = 7.6 Hz, 0.54 H, GlcNAc-2 H-1 of α anomer), 4.58 (d, J = 7.6 Hz, 0.46 H, GlcNAc-2 H-1 of β anomer), 4.54 (d, J = 8.4 Hz, 1 H, GlcNAc-3 H-1), 4.22 (d, J = 2.8 Hz, 1 H), 4.18 (d, J = 1.7 Hz, 1 H), 3.86-3.93 (m, 7 H), 3.64-3.80 (m, 13 H), 3.57-3.64 (m, 3 H), 3.55 (t, J = 8.3 Hz, 1 H), 3.48-3.52 (m, 2 H), 3.41-3.47 (m, 3 H), 2.06 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac); ¹³C NMR (D₂O, 125 MHz): δ 174.8, 174.7, 174.5, 174.4, 101.4 (GlcNAc-2 C-1), 99.9 ($J_{C, H}$ = 173.3 Hz, Man₂ C-1), 99.6 (GlcNAc-3 C-1), 99.5 ($J_{C, H}$ = 164.4 Hz, Manβ C-1), 94.8 (GlcNAc-1 C-1 of β anomer), 80.4, 79.7, 79.2, 78.8, 76.4, 76.2, 75.8, 74.5, 73.5, 73.2, 72.4, 72.0, 70.3, 70.0, 69.9, 69.6, 69.3, 69.2, 67.3, 65.9, 61.7, 60.8, 60.6, 60.1, 60.0, 56.1, 55.3, 55.0, 53.6, 22.3, 22.2, 22.1, 21.9; ESI-MS: [M+H]+ C₃₆H₆₂N₃O₂₆ calcd for 952.3622, found 974.3637.

Benzyl 3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tri-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 3)$ -[3,4,6-O-tri-acetyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tri-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 6)$]-O-2,4-O-di-benzyl- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-di-benzyl-2-deoxy-phthalimido- β -D-di-benzyl-2-deoxy-phthalimido- β -D-di-benzyl-2-deoxy-phthalimido- β -D-di-benzyl-2-deoxy-phthalimido- β -D-di-benzyl-2-deoxy-phthalimido- β -D-di-benzyl-2-



Compound 7 (300 mg, 0.126 mmol) was glycosylated with 3 (149 mg, 0.164 mmol) by following general procedure A to get the desired compound 9 (338 mg, 83%) as colorless oil. $[\alpha]_{D}^{20}$ 15.9 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.87 (d, J = 7.3 Hz, 1 H), 7.74 (t, J = 7.6 Hz, 1 H), 7.63-7.70 (m, 4 H), 7.33-7.41 (m, 8 H), 7.20-7.32 (m, 32 H), 7.12-7.19 (m, 15 H), 7.04-7.10 (m, 8 H), 6.95-7.02 (m, 8 H), 6.88-6.92 (m, 5 H), 6.76-6.82 (m, 5 H), 6.64 (t, J = 7.4Hz, 1 H), 5.40 (t, J = 9.4 Hz, 1 H), 5.21 (d, J = 7.7 Hz, 1 H), 4.93-5.01 (m, 5 H), 4.82-4.91 (m, 5 H), 4.76-4.79 (m, 2 H), 4.68-4.74 (m, 3 H), 4.61-4.68 (m, 3 H), 4.32-4.54 (m, 15 H), 4.26-4.31 (m, 1 H), 4.09-4.24 (m, 10 H), 4.04-4.06 (m, 1 H), 3.95-4.00 (m, 3 H), 3.88-3.91 (m, 2 H), 3.68-3.83 (m, 8 H), 3.60-3.62 (m, 1 H), 3.42-3.56 (m, 6 H), 3.25-3.40 (m, 6 H), 3.20-3.24 (m, 1 H), 3.11-3.17 (m, 2 H), 2.91 (dd, J = 11.5, 5.7 Hz, 1 H), 2.79 (d, J = 9.5 Hz, 1 H), 2.63-2.67 (m, 1 H),2.37-2.40 (m, 1 H), 2.29-2.32 (m, 1 H), 2.00 (s, 3 H, Ac), 1.96 (s, 3 H, Ac), 1.83 (s, 3 H, Ac); ¹³C NMR (CDCl₃, 100 MHz): δ171.2, 170.7, 170.1, 169.2, 168.1, 167.6, 167.4, 139.1, 139.0, 138.9, 138.8, 138.7, 138.6, 138.4 (2 C), 138.3, 138.1 (2 C), 137.8, 137.2, 133.4, 131.9, 131.7, 131.4, 129.1, 128.8, 128.6, 128.4, 128.3 (3 C), 128.2, 128.1 (3 C), 128.0 (2 C), 127.9 (2 C), 127.8, 127.7, 127.5 (2 C), 127.4 (3 C), 127.2, 126.8, 126.0, 123.1, 101.9, 98.6, 97.7, 97.1, 96.9, 96.7, 95.8, 80.7, 80.0, 79.4, 78.8, 78.3, 77.7, 77.2, 76.7, 75.8, 75.1, 74.8, 74.7, 74.6 (2 C), 74.5, 74.4 (2 C), 74.1, 74.0, 73.9, 73.5, 73.4, 72.9 (2 C), 72.6, 72.4 (2 C), 72.3, 71.9, 71.7 (2 C), 71.1, 71.0, 70.7, 70.5, 70.4 (2 C), 70.0, 69.5, 69.2, 68.7, 68.6, 68.4, 68.1, 67.6, 66.8, 63.8, 61.9, 61.8, 61.4, 60.4, 56.7, 55.8, 55.7, 54.2, 53.8, 20.7, 20.6, 20.5; MALDI-MS: [M+Na]+ C₁₉₂H₁₈₆N₄O₄₃Na calcd for 3258.2389, found 3258.2169

 $\label{eq:2-deoxy-acetamido-β-D-glucopyranosyl-(1-2)-α-D-Mannopyranosyl-(1-3)-[3,4,6-O-tri-acetyl-2-deoxy-acetamido-β-D-glucopyranosyl-(1-2)-α-D-Mannopyranosyl-(1-6)]-β-D-Mannopyranosyl-(1-4)-2-deoxy-acetamido-β-D-glucopyranosyl-(1-4)$



Following the general procedure **C**, and **E**, compound **9** (150 mg, 0.046 mmol) yielded the compound **N110** (45 mg, 69% over three steps). $[\alpha]_D^{20}$ 4.9 (c 0.5, H₂O); ¹H NMR (D₂O, 500 MHz): δ 5.22 (t, J = 10.2 Hz, 1 H), 5.16 (d, J = 1.4 Hz, 0.6 H, GlcNAc-1H1 of α anomer), 5.09

(s, 1 H, Man2 H-1), 5.05 (t, J = 9.3 Hz, 1 H), 4.92 (s, 1 H, Man3 H-1), 4.77 (overlapped with D_2O_1 H, GlcNAc-4 H-1), 4.74 (s, 1 H, Man β H-1), 4.67 (d, J = 6.2 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.59 (d, J = 7.5 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.58 (d, J = 7.5 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.53 (d, J = 8.4 H, 1 H, GlcNAc-3 H-1), 4.40 (dd, J = 12.8, 3.3 Hz, 1 H), 4.22 (d, J = 1.5 Hz, 1 H), 4.16 (d, J = 1.9 Hz, 1 H), 4.10-4.11 (m, 1 H), 3.91-3.97 (m, 3 H), 3.82-3.90 (m, 8 H), 3.69-3.80 (m, 10 H), 3.65-3.68 (m, 2 H), 3.56-3.64 (m, 7 H), 3.53 (t, J = 7.9 Hz, 1 H), 3.49 (t, J = 5.5 Hz, 1 H), 3.47 (t, J = 4.2 Hz, 1 H), 3.44-3.46 (m, 1 H), 3.40-3.42 (m, 2 H), 2.10 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 2.01 (s, 3 H, Ac), 1.97 (s, 3 H, Ac); ¹³C NMR (D₂O, 125 MHz): δ176.5, 174.6 (2 C), 174.5, 174.3, 173.6, 100.3 (GlcNAc-2 C-1), 99.5 (J_{CH} = 161.9 Hz, Man β C-1), 99.0 (J_{CH} = 172.3, 165.5 Hz, Man2 C-1, GlcNAc-3 C-1), 98.8 (GlcNAc-4 C-1), 96.8 (J_{CH} = 171.9 Hz, Man3 C-1), 94.7 (GlcNAc-1 C-1 of β anomer), 90.3 (GlcNAc-1 C-1 of α anomer), 80.3, 79.6, 79.3, 79.1, 76.6, 76.3, 75.7, 74.5, 74.3, 74.2, 73.4, 73.3, 73.2, 72.8, 72.6, 72.3, 71.9, 71.2, 71.0, 70.1, 69.9, 69.8, 69.5, 69.3, 69.1, 68.9, 68.3, 67.2, 65.7, 65.5, 61.6 (2 C), 61.5, 61.4, 60.5, 60.0, 59.9, 59.8, 59.7, 56.0, 55.2, 54.8, 53.5, 53.4, 22.2, 22.1, 22.0, 21.8, 20.3, 20.0, 19.9; ESI-MS: [M+H]+ C₅₆H₉₁N₄O₃₉ calcd for 1443.5260, found 1443.5231

Benzyl 3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tri-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 3)$ -[2-O-acetyl-3,4,6-O-tri-benzyl- α -D-Mannopyranosyl $(1\rightarrow 6)$]-O-2,4-O-di-benzyl- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-di-benzyl-2-deoxy-phthalimido- β -



Compound 7 (300 mg, 0.126 mmol) was glycosylated with **2** (88 mg, 0.16 mmol) by following general procedure **A** to get the desired title compound **10** (327 mg, 91%) as colorless oil. $[\alpha]_D^{20}$ - 10.7 (c 0.6, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.84-7.86 (m, 1 H), 7.56-7.76 (m, 7 H), 7.46-7.50 (m, 5 H), 7.12-7.45 (m, 61 H), 7.05-7.10 (m, 7 H), 6.90-6.98 (m, 5 H), 6.70-6.85 (m, 6 H), 5.38 (s, 1 H), 5.29 (d, *J* = 5.5 Hz, 1 H), 5.01-5.10 (m, 3 H), 4.86-4.97 (m, 6 H), 4.72-4.84 (m, 4 H), 4.37-4.69 (m, 20 H), 4.16-4.37 (m, 10 H), 4.05-4.15 (m, 3 H), 3.96-4.04 (m, 3 H), 3.91-3.94 (m, 1 H), 3.76-3.89 (m, 5 H), 3.66-3.74 (m, 4 H), 3.50-3.64 (m, 6 H), 3.41-3.47 (m, 2 H), 3.30-3.36 (m, 2 H), 3.15 (d, *J* = 9.6 Hz, 1 H), 2.97 (d, *J* = 9.4 Hz, 1 H), 2.79 (t, *J* = 8.0 Hz, 1 H), 1.89 (s, 3 H, Ac); ¹³C NMR (CDCl₃, 100 MHz): δ 176.7, 171.2, 170.1, 169.8, 168.2, 167.7, 167.5, 139.0, 138.9, 138.8, 138.6 (2 C), 138.5 (2 C), 138.3 (3 C), 138.2, 138.1, 138.0, 137.9 (2 C), 137.3, 133.5, 132.0, 131.8, 128.9, 128.6, 128.5 (2 C), 128.4 (2 C), 128.3, 128.2, 128.1, 128.0 (3 C), 127.9 (3 C), 127.8 (2 C), 127.7, 127.6 (2 C), 127.5 (2 C), 127.4 (3 C), 126.9 (2 C), 126.4, 123.1, 101.5, 98.7, 98.3, 97.2 (2 C), 96.1, 81.1, 79.5, 79.3, 79.0, 78.3, 77.8, 77.7, 77.5, 76.8, 76.6, 76.5, 76.2, 76.1, 75.2, 74.9, 74.8, 74.7 (2 C), 74.6, 74.5, 74.3 (2 C), 74.2 (2 C), 73.9, 73.5, 73.4,

73.3, 73.0, 72.7 (2 C), 72.6, 72.5, 71.7, 71.2, 70.8, 70.6, 70.5, 69.0, 68.9, 68.8, 68.2, 67.8, 66.5, 60.4, 56.6, 55.9, 55.8, 20.8; MALDI-MS: [M+Na]+ C₁₇₄H₁₆₉N₃O₃₅Na calcd for 2883.1434, found 2883.1833

2-deoxy-acetamido- β -D-glucopyranosyl- $(1\rightarrow 2)-\alpha$ -D-Mannopyranosyl- $(1\rightarrow 3)-[\alpha$ -D-Mannopyranosyl $(1\rightarrow 6)$]-O- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -2-deoxy-acetamido- β -D-glucopyranoside (N030):



Following the general procedure **C**, **D** and **E**, compound **10** (150 mg, 0.05 mmol) yielded the compound **N030** (31 mg, 53% over four steps). $[\alpha]_D^{20}$ 20.6 (c 0.5, H₂O); ¹H NMR (D₂O, 500 MHz): δ 5.17 (d, J = 2.0 Hz, 0.6 H, GlcNAc-1 H1 of α anomer), 5.10 (s, 1 H, Man2 H-1), 4.90 (s, 1 H, Man3 H-1), 4.77 (s, 1 H, Man β H-1), 4.68 (d, J = 7.8 Hz, 1 H, GlcNAc-1 H-1 of β anomer), 4.59 (d, J = 7.9 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.58 (d, J = 7.9 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.53 (d, J = 8.4 Hz, 1 H, GlcNAc-3 H-1), 4.24 (brs, 1 H), 4.17-4.18 (m, 1 H), 3.95-3.97 (m, 1 H), 3.84-3.92 (m, 9 H), 3.70-3.80 (m, 11 H), 3.67-3.69 (m, 1 H), 3.65-3.66 (m, 1 H), 3.58-3.64 (m, 7 H), 3.54 (t, J = 8.4 Hz, 1 H), 3.48 (t, J = 9.8 Hz, 1 H), 3.41-3.44 (m, 2 H), 2.06 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.02 (s, 3 H, Ac); ¹³C NMR (D₂O, 125 MHz): δ 174.7, 174.6, 174.3, 101.2 (GlcNAc-2, C-1), 100.3 ($J_{C,H} = 161.6$ Hz, Man β , C-1), 99.5 ($J_{C,H} = 174.4$, 172.7, 161.6 Hz, 3 C, Man2 C-1, Man3 C-1, GlcNAc-3 C-1), 94.7 (GlcNAc-1 C-1 of β anomer), 90.3 (GlcNAc-1 C-1 of α anomer), 80.3, 79.5, 79.1, 76.3, 75.7, 74.5, 74.2, 74.0, 73.4, 73.1, 72.6, 72.3, 71.9, 70.3, 70.0, 69.9, 69.8, 69.3, 69.1, 67.2, 66.6, 65.8, 61.6, 60.8, 60.5, 59.8, 56.0, 55.2, 54.8, 53.5, 22.2, 22.1, 21.7; ESI-MS: [M+H]+ C₄₂H₇₂N₃O₃₁ calcd for 1114.4150, found 1114.4170

Benzyl 2-O-acetyl-3,4,6-O-tri-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 3)$ -2-O-benzyl-4,6-benzylidene- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranoside (11):



Compound **1** (300 mg, 0.22 mmol) was glycosylated with **2** (150 mg, 0.28 mmol) by following general procedure **A** to get the desired compound **11** (382 mg, 95%) as colorless oil. $[\alpha]_D^{20}$ 7.68 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.93 (d, *J* = 6.7 Hz, 1 H), 7.75-7.78 (m, 4 H), 7.67-7.69 (m, 2 H), 7.48-7.50 (m, 4 H), 7.30-7.45 (m, 28 H), 7.23-7.28 (m, 4 H), 7.09-7.13 (m, 1 H), 7.03-7.07 (m, 5 H), 6.98-7.01 (m, 3 H), 6.94-6.96 (m, 3 H), 6.80-6.83 (m, 3 H), 5.67 (t, *J* = 2.0 Hz, 1 H), 5.56 (s, 1 H), 5.40 (d, *J* = 1.1 Hz, 1 H), 5.37 (d, *J* = 8.0 Hz, 1 H), 5.04 (d, *J* = 8.2 Hz, 1 H), 4.98 (d, *J* = 12.3 Hz, 1 H), 4.96 (d, *J* = 10.8 Hz, 1 H), 4.92 (d, *J* = 1.0 Hz, 12.1 Hz, 1

H), 4.88 (d, J = 12.8 Hz, 1 H), 4.77 (d, J = 12.4 Hz, 1 H), 4.76 (d, J = 11.1 Hz, 1 H), 4.71 (d, J = 12.7 Hz, 1 H), 4.68 (d, J = 8.4 Hz, 1 H), 4.61-4.64 (m, 3 H), 4.55-4.58 (m, 3 H), 4.52 (d, J = 6.0 Hz, 1 H), 4.48-4.49 (m, 2 H), 4.44-4.47 (m, 2 H), 4.25-4.35 (m, 4 H), 4.18-4.23 (m, 2 H), 4.14-4.16 (m, 1 H), 4.12 (t, J = 9.5 Hz, 1 H), 4.05 (dd, J = 8.5, 3.2 Hz, 1 H), 3.91-3.94 (m, 2 H), 3.82-3.88 (m, 3 H), 3.69-3.75 (m, 2 H), 3.64-3.67 (m, 1 H), 3.51-3.58 (m, 2 H), 3.46 (dd, J = 11.5, 2.6 Hz, 1 H), 3.39 (dd, J = 9.8, 2.4 Hz, 1 H), 3.26-3.29 (m, 1 H), 3.12-3.18 (m, 1 H), 2.16 (s, 3 H, Ac); ¹³C NMR (CDCl₃, 100 MHz): δ 176.6, 170.1, 167.7, 138.9, 138.7, 138.6, 138.5, 138.4, 138.2, 137.9 (2 C), 137.4, 137.3, 133.5, 131.8, 128.8, 128.7, 128.5 (2 C), 128.4 (2 C), 128.3, 128.2, 128.1 (3 C), 127.9 (3 C), 127.8, 127.7, 127.6 (3 C), 127.5, 127.4 (2 C), 127.0, 126.9, 126.1, 123.2, 101.6, 101.1, 98.8, 97.2, 97.1, 79.0, 78.8, 78.5, 78.1, 77.4, 77.1, 76.6, 76.5, 76.1, 75.8, 75.5 (2 C), 74.9, 74.8, 74.7, 74.6, 74.4, 74.3, 73.6, 73.3, 72.8, 72.7, 72.5, 72.3, 71.7, 70.6, 69.0, 68.9, 68.4, 67.8, 67.0, 56.7, 55.8, 21.1; MALDI-MS: [M+Na]+ C₁₁₂H₁₀₈N₂O₂₄Na calcd for 1887.7190, found 1887.7325

Benzyl 2-O-acetyl-3,4,6-O-tri-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 3)$ -2,4-O-di-benzyl- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranoside (12):



Compound **11** (300 mg, 0.16 mmol) was treated by following general procedure **B** to get the desired title compound **12** (276 mg, 92%) as white foam. $[\alpha]_D^{20}$ 3.68 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.94-7.96 (m, 1 H), 7.75-7.78 (m, 3 H), 7.67-7.69 (m, 2 H), 7.48-7.50 (m, 2 H), 7.28-7.45 (m, 33 H), 7.23-7.26 (m, 3 H), 7.04-7.08 (m, 6 H), 6.97-7.01 (m, 5 H), 6.82-6.84 (m, 3 H), 5.57-5.58 (m, 1 H), 5.39 (d, *J* = 7.8 Hz, 1 H, H-1), 5.27 (d, *J* = 0.9 Hz, 1 H, Man H-1), 5.02-5.07 (m, 3 H), 4.87-4.97 (m, 3 H), 4.77-4.82 (m, 2 H), 4.67-4.73 (m, 3 H), 4.56-4.66 (m, 5 H), 4.51-4.55 (m, 3 H), 4.44-4.50 (m, 3 H), 4.23-4.36 (m, 5 H), 4.12-4.18 (m, 1 H), 4.05 (dd, *J* = 9.1, 3.2 Hz, 1 H), 3.98-4.01 (m, 1 H), 3.83-3.95 (m, 3 H), 3.71-3.80 (m, 5 H), 3.65-3.68 (m, 1 H), 3.46-3.57 (m, 3 H), 3.40-3.43 (m, 1 H), 3.31-3.33 (m, 1 H), 3.15-3.18 (m, 1 H), 2.18 (s, 3 H, Ac); ¹³C NMR (CDCl₃, 100 MHz): δ 176.7, 170.1, 167.7, 138.8, 138.7, 138.6, 138.1, 138.0, 137.9, 137.8, 137.3, 133.6, 131.8, 128.7, 128.5 (3 C), 128.4 (2 C), 128.3 (2 C), 128.2 (3 C), 128.1, 128.0, 127.9 (3 C), 127.8 (3 C), 127.6 (2 C), 127.5, 127.2, 127.1, 126.9, 123.2, 100.9, 99.7, 97.2, 80.7, 78.5, 78.3, 78.0, 77.1, 76.7, 76.0, 75.6, 75.1, 75.0 (2 C), 74.7, 74.6, 74.5, 73.6, 73.3, 72.8, 72.7, 72.5, 72.4, 71.9, 70.6, 69.2, 68.8, 68.3, 67.8, 67.6, 62.1, 56.6, 55.9, 21.1; MALDI-MS: [M+Na]+ C₁₁₂H₁₁₀N₂O₂₄Na calcd for 1889.7346, found 1889.7427

Benzyl 2-O-acetyl-3,4,6-O-tri-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 3)$ -[3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tri-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 6)$]-2,4-O-di-benzyl- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-di-benzyl-2-deoxy- β -2-deoxy- β -2-



Compound 12 (300 mg, 0.16 mmol) was glycosylated with 4 (220 mg, 0.21 mmol) by following general procedure A to get the desired α anomer 13 (347 mg, 76%) and β -anomer 13' (69 mg, 15%) as colorless oil. $[\alpha]_{D}^{20}$ 13.7 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 500 MHz): δ 7.81 (d, J = 7.3 Hz, 1 H), 7.69 (t, J = 7.3 Hz, 1 H), 7.60-7.64 (m, 3 H), 7.49-7.52 (m, 3 H), 7.39-7.43 (m, 4 H), 7.06-7.43 (m, 59 H), 6.99-7.03 (m, 2 H), 6.90-6.98 (m, 11 H), 6.85-6.89 (m, 5 H), 6.69-6.74 (m, 3 H), 6.61 (t, J = 7.5 Hz, 1 H), 6.53 (t, J = 7.3 Hz, 1 H), 5.47 (s, 1 H), 5.19 (d, J = 7.8 Hz, 1 H), 5.11 (s, 1 H), 4.99 (d, J = 12.0 Hz, 1 H), 4.91 (d, J = 8.5 Hz, 1 H), 4.87 (d, J = 13.0 Hz, 1 H), 4.85 (d, J = 15.5 Hz, 1 H), 4.74-4.80 (m, 4 H), 4.62-4.69 (m, 4 H), 4.54-4.62 (m, 4 H), 4.40-4.55(m, 10 H), 4.32-4.36 (m, 4 H), 4.26 (dd, J = 11.4, 4.4 Hz, 1 H), 4.10-4.19 (m, 6 H), 4.05-4.09 (m, 2 H), 3.98-4.02 (m, 3 H), 3.90-3.97 (m, 2 H), 3.80-3.88 (m, 4 H), 3.73-3.80 (m, 2 H), 3.63-3.71 (m, 4 H), 3.56-3.62 (m, 4 H), 3.47-3.52 (m, 2 H), 3.29-3.42 (m, 6 H), 3.22-3.26 (m, 1 H), 3.12-3.19 (m, 2 H), 3.08-3.10 (m, 1 H), 2.74 (dd, J = 11.1, 6.2 Hz, 1 H), 2.59-2.63 (m, 1 H), 2.05 (s, 3 H. Ac): ¹³C NMR (CDCl₃, 125 MHz): δ177.2, 169.9, 167.9, 167.5, 167.3, 138.9, 138.8, 138.6, 138.5 (2 C), 138.4, 138.2, 137.9, 137.7, 133.4, 131.8, 131.7, 131.4, 128.6, 128.5, 128.3, 128.2 (2 C), 128.1 (2 C), 128.0, 127.9, 127.8, 127.7 (2 C), 127.5 (2 C), 127.4, 127.2, 127.1, 127.0 (2 C), 126.8, 123.4, 123.0, 102.3 ($J_{CH} = 157.9$ Hz), 99.5 ($J_{CH} = 176.2$ Hz), 97.8 ($J_{CH} = 170.2$ Hz), 97.0 $(J_{CH} = 164.5 \text{ Hz}), 96.8 (J_{CH} = 166.2 \text{ Hz}), 96.7 (J_{CH} = 169.8 \text{ Hz}), 81.0, 80.2, 79.2, 78.8, 78.1,$ 77.9, 76.5, 75.6, 74.9, 74.7, 74.6, 74.5, 74.4, 74.3, 74.1, 74.0, 73.9, 73.4 (2 C), 73.0, 72.6, 72.4, 72.3, 72.1, 71.7, 70.4, 69.6, 68.9, 68.7, 68.1, 67.4, 66.9, 56.6, 55.7, 55.5, 20.9; MALDI-MS: $[M+Na]+C_{174}H_{169}N_{3}O_{35}Na$ calcd for 2883.1434, found 2883.1873

Benzyl 2-O-acetyl-3,4,6-O-tri-benzyl-α-D-Mannopyranosyl-(1→3)-[3,4,6-O-tri-benzyl-2deoxy-phthalimido-β-D-glucopyranosyl-(1→2)-3,4,6-O-tri-benzyl-β-D-Mannopyranosyl-(1→6)]-2,4-O-di-benzyl-β-D-Mannopyranosyl-(1→4)-3,6-O-di-benzyl-2-deoxyphthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -Dglucopyranoside (13'): $[\alpha]_D^{20}$ 11.8 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 500 MHz): δ 7.61-7.63 (m, 1 H), 7.50-7.56 (m, 4 H), 7.35-7.45 (m, 10 H), 7.10-7.33 (m, 54 H), 7.02-7.06 (m, 3 H), 6.93-7.01 (m, 9 H), 6.71-6.623 (m, 7 H), 6.65-6.68 (m, 2 H), 6.59-6.62 (m, 2 H), 5.44 (d, J = 8.8 Hz, 1 H), 5.43 (s, 1 H), 5.34 (d, J = 7.8 Hz, 1 H), 5.15 (s, 1 H), 4.98-5.02 (m, 2 H), 4.95 (d, J = 8.4 Hz, 1 H), 4.81-4.87 (m, 3 H), 4.67-4.75 (m, 7 H), 4.57-4.64 (m, 4 H), 4.49-4.55 (m, 4 H), 4.30-4.48 (m, 16 H), 4.22-4.28 (m, 2 H), 4.15-4.21 (m, 3 H), 4.13 (dd, J = 14.3, 7.2 Hz, 1 H), 4.02-4.08 (m, 2 H), 4.00 (t, J = 9.2 Hz, 1 H), 3.94-3.97 (m, 2 H), 3.80-3.91 (m, 7 H), 3.75-3.77 (m, 1 H), 3.60-3.70 (m, 3 H), 3.52-3.59 (m, 3 H), 3.35-3.47 (m, 5 H), 3.23-3.28 (m, 1 H), 3.10-3.14 (m, 1 H), 2.98-3.02 (m, 1 H), 2.05 (s, 3 H, Ac); ¹³C NMR (CDCl₃, 125 MHz): δ169.9, 168.3, 168.2, 167.9, 167.5, 167.2, 139.4, 139.3, 139.0, 138.7, 138.6, 138.5, 138.2, 138.0, 137.8, 137.2, 136.8, 133.8, 133.5, 132.9, 132.0, 131.7 (2 C), 131.5, 128.9, 128.7, 128.5, 128.4, 128.3 (2 C), 128.1, 128.0, 127.8 (2 C), 127.7, 127.5, 127.4, 127.3, 127.1, 127.0, 126.8, 126.7, 123.3, 123.0, 122.5, 100.6

 $(J_{C,H} = 160.7 \text{ Hz}), 100.3 (J_{C,H} = 159.2 \text{ Hz}), 99.5 (J_{C,H} = 174.7 \text{ Hz}), 99.1 (J_{C,H} = 170.1 \text{ Hz}), 98.1 (J_{C,H} = 168.8 \text{ Hz}), 97.0 (J_{C,H} = 166.0 \text{ Hz}), 81.0, 79.4, 78.9, 78.0, 77.7, 76.4, 75.9, 75.6, 74.6, 74.5, 74.4, 74.2, 74.1, 73.5, 73.4, 73.3, 73.2, 72.7, 72.6, 72.3, 71.4, 69.6, 69.3, 68.8, 68.6, 67.8, 67.1, 66.8, 56.4, 56.2, 55.8, 54.6, 20.9; MALDI-MS: [M+Na]+ C_{174}H_{169}N_3O_{35}Na calcd for 2883.1434, found 2883.2833$

 α -D-Mannopyranosyl-(1 \rightarrow 3)-[2-deoxy-acetamido- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-Mannopyranosyl-(1 \rightarrow 6)]-O- β -D-Mannopyranosyl-(1 \rightarrow 4)-2-deoxy-acetamido- β -D-glucopyranoside (N050):



Following the general procedure **C**, **D** and **E**, compound **13** (150 mg, 0.05 mmol) yielded the compound **N050** (32 mg, 55% over four steps). $[\alpha]_D^{20}$ 6.78 (c 0.5, H₂O); ¹H NMR (D₂O, 500 MHz): δ 5.17 (d, J = 2.3 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.08 (s, 1 H, Man₂ H-1), 4.90 (s, 1 H, Man₃ H-1), 4.75 (s, 1 H, Man β H-1), 4.67 (d, J = 8.0 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.59 (d, J = 7.8 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.58 (d, J = 7.8 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.53 (d, J = 8.4 Hz, 1 H, GlcNAc-3 H-1), 4.23 (d, J = 1.6 Hz, 1 H), 4.09 (d, J = 1.8 Hz, 1 H), 4.04 (dd, J = 3.1, 1.6 Hz, 1 H), 3.94 (dd, J = 11.0, 5.5 Hz, 1 H), 3.84-3.91 (m, 7 H), 3.65-3.80 (m, 14 H), 3.57-3.65 (m, 7 H), 3.51 (t, J = 8.5 Hz, 1 H), 3.42-3.49 (m, 2 H), 3.40-3.42 (m, 1 H), 2.06 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.02 (s, 3 H, Ac); ¹³C NMR (D₂O, 125 MHz): δ 174.7, 174.6, 174.5, 174.4, 102.4 ($J_{C,H}$ = 173.6 Hz, Man2 C-1), 101.3 (GlcNAc-2 C-1), 100.3 ($J_{C,H}$ = 161.9 Hz, Man β C-1), 99.5 (GlcNAc-3 C-1), 96.9 ($J_{C,H}$ = 171.9 Hz, Man3 C-1), 94.7 (GlcNAc-1 C-1 of β anomer), 90.3 (GlcNAc-1 C-1 of α anomer), 80.5, 79.6, 79.4, 79.1, 76.1, 75.7, 74.5, 74.3, 74.2, 73.3, 73.2, 72.7, 72.4, 71.9, 70.2, 70.0, 69.9, 69.8, 69.5, 69.3, 69.1, 67.2, 66.7, 65.7, 65.5, 61.5, 61.0, 60.5, 50.9, 56.0, 55.2, 54.8, 53.5, 22.2, 22.1, 22.0, 21.8; ESI-MS: [M+H]+ C₄₂H₇₂N₃O₃₁ calcd for 1114.4150, found 1114.4105

Benzyl 2,3-O-di-benzyl-4,6-O-benzylidene- β -D-Mannopyranosyl- $(1 \rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1 \rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranoside (14):



Compound 1 (500 mg, 0.36 mmol) was dissolved in dry DMF (10 mL). NaH (26 mg, 0.65 mmol), Bu₄NI (15 mg, 0.04 mmol), followed by BnBr (64 μ L, 0.54 mmol) were added at 0 °C,

and the reaction mixture was stirred under argon for 4 h. The solvent was evaporated, and the residue was diluted with ethyl acetate and washed with water and a brine solution. After dried over Na₂SO₄, the organic layer was evaporated. The residue was purified on a silica gel column (Hexanes: EtOAc = 3:1) to afford the product 14 (479 mg, 90%) as colorless oil. $\left[\alpha\right]_{D}^{20}$ 19.2 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.90 (d, J = 6.8 Hz, 1 H), 7.66-7.76 (m, 5 H), 7.48-7.50 (m, 4 H), 7.21-7.41 (m, 26 H), 7.05-7.08 (m, 1 H), 6.96-7.02 (m, 6 H), 6.89-6.91 (m, 3 H), 6.77-6.80 (m, 2 H), 5.53 (s, 1 H), 5.32 (d, J = 8.0 Hz, 1 H), 4.99 (d, J = 8.2 Hz, 1 H), 4.85-4.95 (m, 4)H), 4.77 (d, J = 12.4 Hz, 1 H), 4.73 (d, J = 12.4 Hz, 1 H), 4.61 (d, J = 12.4 Hz, 1 H), 4.59 11.2 Hz, 2 H), 4.56 (d, J = 12.3 Hz, 2 H), 4.30 (dd, J = 7.0, 2.4 Hz, 1 H), 4.26-4.27 (m, 1 H), 4.23-4.25 (m, 1 H), 4.22 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.13-4.16 (m, 2 H), 4.10 (t, J = 2.7 Hz, 1 H), 4.18-4.20 (m, 1 H), 4.189.6 Hz, 2 H), 3.79 (d, J = 3.0 Hz, 1 H), 3.64-3.66 (m, 1 H), 3.59-3.62 (m, 1 H), 3.56 (t, J = 10.3 Hz)Hz, 1 H), 3.49 (dd, J = 8.8, 3.7 Hz, 1 H), 3.44 (dd, J = 10.4, 2.5 Hz, 1 H), 3.35 (dd, J = 9.8, 2.4 Hz, 1 H), 3.23-3.26 (m, 1 H), 3.13-3.19 (m, 1 H); ¹³C NMR (CDCl₃, 100 MHz): δ171.2, 167.6, 162.6. 138.9, 138.7 (2 C), 138.6 (2 C), 137.9, 137.7, 137.2, 133.5, 131.7, 128.8, 128.5, 128.4, 128.3 (2 C), 128.2 (2 C), 128.1, 127.8, 127.7 (2 C), 127.6 (2 C), 127.5 (2 C), 127.4 (2 C), 126.9 (2 C), 126.1, 123.1, 101.8, 101.3, 97.2, 97.1, 79.3, 78.7, 78.4, 77.3, 77.1, 76.6, 75.8, 75.2, 74.7, 74.6, 74.5, 74.3, 73.3, 72.7, 72.6, 70.5, 68.6, 68.2, 68.0, 67.3, 60.4, 56.6, 55.8; MALDI-MS: $[M+Na]+C_{90}H_{84}N_2O_{18}Na$ calcd for 1503.5617, found 1503.5415

Benzyl 2,3,4-O-tri-benzyl- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranoside (15):

The compound **14** (400 mg, 0.27 mmol) was treated accordingly to the general procedure **B** to afford trisaccharide acceptor **15** (380 mg, 95%). $[\alpha]_D^{20}$ 16.2 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.95-7.96 (m, 1 H), 7.76-7.79 (m, 3 H), 7.69-7.71 (m, 2 H), 7.53-7.55 (m, 2 H), 7.46-7.47 (m, 2 H), 7.28-7.43 (m, 21 H), 7.05-7.12 (m, 7 H), 6.97-7.01 (m, 5 H), 6.84-6.86 (m, 3 H), 5.41 (d, *J* = 8.0 Hz, 1 H), 5.07 (s, 1 H), 5.06 (d, *J* = 9.6 Hz, 1 H), 4.94-4.97 (m, 4 H), 4.79 (d, *J* = 12.3 Hz, 1 H), 4.63-4.69 (m, 5 H), 4.59-4.61 (m, 3 H), 4.54 (d, *J* = 3.6 Hz, 1 H), 4.51 (d, *J* = 3.8 Hz, 1 H), 4.47 (d, *J* = 12.4 Hz, 1 H), 4.24-4.41 (m, 5 H), 4.18-4.21 (m, 1 H), 4.13 (t, *J* = 9.1 Hz, 1 H), 3.84-3.91 (m, 2 H), 3.73-3.81 (m, 2 H), 3.68 (d, *J* = 10.7 Hz, 1 H), 3.53-3.58 (m, 2 H), 3.47-3.49 (m, 1 H), 3.39-3.44 (m, 2 H), 3.26-3.29 (m, 1 H); ¹³C NMR (CDCl₃, 100 MHz): δ 171.2, 168.6, 167.7 (2C), 138.8, 138.7, 138.6, 138.4 (2 C), 138.0, 137.3, 133.6, 131.7, 128.7, 128.5 (2 C), 128.3 (2 C), 128.2 (2 C), 128.1 (2 C), 127.9, 127.8 (2 C), 127.6 (3 C), 127.4, 127.3, 127.2, 126.9, 123.2, 101.1, 97.2 (2 C), 82.6, 79.0, 77.1, 76.6, 75.9, 75.7, 75.3, 75.2, 74.9, 74.7 (2 C), 74.6, 74.5 (2 C), 73.4, 72.8, 71.9, 70.6, 68.3, 68.0, 62.4, 60.5, 56.6, 55.9; MALDI-MS: [M+Na]+ C₉₀H₈₆N₂O₁₈Na calcd for 1505.5773, found 1505.5615

Benzyl 3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tri-benzyl- α -Mannopyranosyl- $(1\rightarrow 6)$ -2,3,4-O-tri-benzyl- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranoside (16):



Compound 15 (300 mg, 0.20 mmol) was glycosylated with 4 (277 mg, 0.26 mmol) by following general procedure A to get the desired α anomer compound 16 (350 mg, 71%) and β anomer 16' (100 mg, 20%) as colorless oil. $[\alpha]_{D}^{20}$ 5.9 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 500 MHz): δ 7.83 (d, J = 5.7 Hz, 1 H), 7.71 (t, J = 5.7 Hz, 1 H), 7.57-7.67 (m, 4 H), 7.46-7.49 (m, 2 H), 7.40-7.43 (m, 2 H), 7.23-7.36 (m, 30 H), 7.13-7.20 (m, 10 H), 7.07-7.12 (m, 9 H), 6.91-7.02 (m, 14 H), 6.86-6.91 (m, 3 H), 6.73-6.79 (m, 3 H), 6.68-6.71 (m, 2 H), 6.59-6.63 (m, 1 H), 5.26 (d, J = 6.7 Hz, 1 H), 4.92-5.00 (m, 4 H), 4.78-4.87 (m, 4 H), 4.68-4.75 (m, 4 H), 4.59-4.64 (m, 3 H), 4.45-4.56 (m, 9 H), 4.36-4.43 (m, 4 H), 4.24-4.30 (m, 4 H), 4.17-4.23 (m, 4 H), 4.11-4.15 (m, 3 H), 4.03-4.08 (m, 2 H), 3.91 (t, J = 7.6 Hz, 1 H), 3.84 (d, J = 1.6 Hz, 1 H), 3.81 (d, J = 2.6 Hz, 1 H), 3.70-3.77 (m, 3 H), 3.60-3.64 (m, 2 H), 3.54-3.59 (m, 2 H), 3.45-3.51 (m, 2 H), 3.39-3.44 (m, 3 H), 3.35-3.38 (m, 2 H), 3.28-3.30 (m, 2 H), 3.17-3.22 (m, 2 H), 2.88-2.92 (m, 1 H), 2.79 (dd, J = 8.8, 4.8) Hz, 1 H); 13 C NMR (CDCl₃, 125 MHz): δ 168.3, 168.1, 167.6, 167.5, 139.1, 139.0, 138.7, 138.6, 138.5 (2 C), 138.3, 138.2, 138.1, 138.0, 137.2, 133.8, 133.5, 133.4, 131.9, 131.7 (2 C), 131.5, 128.5, 128.4, 128.3, 128.2, 128.1 (2 C), 127.9, 128.0, 127.7, 127.6, 127.5 (2 C), 127.4, 127.3, 127.2, 127.1, 126.9, 126.8, 123.5, 123.1, 102.6 (*J*_{C,H} = 157.5 Hz), 97.7 (*J*_{C,H} = 171.4 Hz), 97.1 $(J_{CH} = 169.2.4 \text{ Hz}), 96.9 (J_{CH} = 166.0 \text{ Hz}), 96.8 (J_{CH} = 170.1 \text{ Hz}), 83.0, 80.4, 79.4, 79.0, 76.9,$ 76.4, 75.5, 75.1, 74.8, 74.6, 74.5, 74.4, 74.3, 74.0, 73.9, 73.8, 73.4, 73.2, 72.6, 72.5, 72.0, 71.8, 70.5, 69.8, 69.7, 68.9, 68.2, 68.0, 66.9, 60.4, 56.7, 55.7, 55.6; MALDI-MS: [M+Na]+ C₁₅₂H₁₄₅N₃O₂₉Na calcd for 2498.9861, found 2499.1289

Benzyl 3,4,6-O-tri-benzyl-2-deoxy-phthalimido-β-D-glucopyranosyl-(1→2)-3,4,6-O-tribenzyl-β-Mannopyranosyl-(1→6)-2,3,4-O-tri-benzyl-β-D-Mannopyranosyl-(1→4)-3,6-O-dibenzyl-2-deoxy-phthalimido-β-D-glucopyranosyl-(1→4)-3,6-O-di-benzyl-2-deoxyphthalimido-β-D-glucopyranoside (16'): $[\alpha]_D^{20}$ 3.9 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 500 MHz): δ 7.59-7.63 (m, 2 H), 7.51-7.57 (m, 5 H), 7.47-7.49 (m, 1 H), 7.40-7.42 (m, 5 H), 7.35-7.38 (m, 5 H), 7.21-7.33 (m, 26 H), 7.14-7.20 (m, 12 H), 7.09-7.12 (m, 3 H), 7.03-7.05 (m, 2 H), 6.94-6.98 (m, 8 H), 6.78-6.85 (m, 7 H), 6.64-6.70 (m, 4 H), 6.57-6.60 (m, 2 H), 5.43 (d, *J* = 6.8 Hz, 1 H), 5.33 (d, *J* = 6.6 Hz, 1 H), 5.01 (d, *J* = 9.0 Hz, 1 H), 4.92-4.98 (m, 3 H), 4.87 (d, *J* = 10.0 Hz, 1 H), 4.81-4.84 (m, 2 H), 4.79 (d, *J* = 3.3 Hz, 1 H), 4.74 (d, *J* = 8.8 Hz, 1 H), 4.67-4.71 (m, 2 H), 4.65 (d, *J* = 3.7 Hz, 1 H), 4.61 (d, *J* = 12.2 Hz, 1 H), 4.56 (d, *J* = 9.6 Hz, 1 H), 4.51-4.53 (m, 1 H), 4.44-4.46 (m, 2 H), 4.39-4.42 (m, 6 H), 4,36-4.37 (m, 2 H), 4.32-4.34 (m, 2 H), 4.29-4.31 (m, 1 H), 4.24-4.26 (m, 1 H), 4.03-4.06 (m, 1 H), 3.95-3.98 (m, 2 H), 3.84 (t, *J* = 7.5 Hz, 1 H), 3.75-3.78 (m, 2 H), 3.68 (d, *J* = 1.4 Hz, 1 H), 3.62-3.64 (m, 1 H), 3.58-3.60 (m, 1 H), 3.27-3.31 (m, 1 H), 3.51-3.53 (m, 2 H), 3.45-3.48 (m, 2 H), 3.43-3.45 (m, 1 H), 3.36-3.42 (m, 4 H), 3.27-3.31 (m, 1 1 H), 3.24-3.27 (m, 1 H), 3.04-3.15 (m, 3 H); ¹³C NMR (CDCl₃, 125 MHz): δ 168.3, 168.2, 167.6, 167.2, 139.6, 139.2, 138.9, 138.8 (2 C), 138.7, 138.6 (2 C), 138.5, 138.2, 137.9, 137.2, 133.7, 133.4, 132.9, 132.1, 131.7, 131.6, 131.5, 128.7, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 127.5, 127.4, 127.3, 127.2, 127.1, 127.0, 126.8, 123.4, 123.1, 100.5 (2 C, $J_{C,H}$ = 159.8 Hz, $J_{C,H}$ = 159.0 Hz), 99.0 ($J_{C,H}$ = 170.2 Hz), 97.7 ($J_{C,H}$ = 170.1 Hz), 97.0 ($J_{C,H}$ = 166.1 Hz), 82.6, 81.1, 79.3, 78.9, 78.8, 77.5, 77.2, 75.6, 75.2, 75.0, 74.6, 74.5, 74.4, 74.2, 73.4, 73.2, 72.9, 72.6, 72.4, 71.6, 70.7, 70.4, 69.7, 69.3, 68.7, 67.9, 60.4, 56.4, 56.2, 55.8; MALDI-MS: [M+Na]+ C_{152}H_{145}N_3O_{29}Na calcd for 2498.9861, found 2499.1369



2-dexoy-acetamido- β -D-glucopyranosyl- $(1 \rightarrow 2)$ - α -Mannopyranosyl- $(1 \rightarrow 6)$ - β -D-Mannopyranosyl- $(1 \rightarrow 4)$ -2-deoxy-acetamido- β -D-glucopyranosyl- $(1 \rightarrow 4)$ -2-deoxyacetamido-β-D-glucopyranoside (N040): Following the general procedure C and E, compound 16 (150 mg, 0.06 mmol) yielded the compound N040 (37 mg, 61% over three steps). $\left[\alpha\right]_{D}^{20}$ 3.9 (c 0.5, H₂O); ¹H NMR (D₂O, 500 MHz): δ 5.16 (d, J = 2.4 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 4.89 (s, 1 H, Man2 H-1), 4.74 (s, 1 H, Man β H-1), 4.67 (d, J = 8.0 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.59 (d, J = 7.8 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.57 (d, J = 7.8 Hz, 0.4 H. GlcNAc-2 H-1 of β anomer), 4.52 (d. J = 8.4 Hz, 1 H. GlcNAc-3 H-1), 4.07-4.08 (m, 1 H), 4.05 (d, J = 1.1 Hz, 1 H), 3.83-3.93 (m, 7 H), 3.71-3.80 (m, 7 H), 3.69-3.71 (m, 1 H), 3.67-3.69 (m, 1 H), 3.65-3.66 (m, 1 H), 3.55-3.64 (m, 7 H), 3.47-3.53 (m, 2 H), 3.38-3.46 (m, 2 H), 2.05 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 2.01 (s, 3 H, Ac); ¹³C NMR (D₂O, 125 MHz): δ174.7, 174.6, 174.5, 174.4, 101.3 (GlcNAc-2 C-1), 100.5 (J_{C,H} = 161.8 Hz, Manβ C-1), 99.5 (GlcNAc-3 C-1), 97.0 $(J_{CH} = 172.7 \text{ Hz}, \text{Man2 C-1}), 94.7$ (GlcNAc-1 C-1 of β anomer), 90.3 (GlcNAc-1 C-1 of α anomer), 81.7, 79.6, 79.4, 79.1, 76.2, 75.7, 74.4, 74.3, 73.3, 72.7, 72.6, 72.4, 71.9, 70.3, 69.9, 69.8, 69.5, 69.3, 69.1, 67.3, 66.5, 66.1, 61.5, 60.5, 59.9, 56.0, 55.2, 54.8, 53.5, 22.2, 22.1, 22.0, 21.8; ESI-MS: [M+H]+ C₃₆H₆₂N₃O₂₆ calcd for 952.3622, found 974.3555

Benzyl 3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl-(1 \rightarrow 2)-3,4,6-O-tribenzyl- α -D-Mannopyranosyl-(1 \rightarrow 3)-2-O-benzyl-4,6-O-benzylidene- β -D-Mannopyranosyl-(1 \rightarrow 4)-3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl-(1 \rightarrow 4)-3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranoside (17):



Compound 1 (300 mg, 0.216 mmol) was glycosylated with 3 (256 mg, 0.28 mmol) by following general procedure A to get the desired compound 17 (388 mg, 94%) as colorless oil. $[\alpha]_D^{20}$ 26.9 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.91 (d, J = 6.8 Hz, 1 H), 7.70-7.77 (m, 5 H), 7.55-7.70 (m, 6 H), 7.49-7.53 (m, 4 H), 7.30-7.40 (m, 12 H), 7.22-7.27 (m, 8 H), 7.17-7.20 (m, 1 H), 7.13-7.16 (m, 2 H), 6.99-7.08 (m, 6 H), 6.90-6.97 (m, 4 H), 6.80-6.85 (m, 3 H), 5.62 (t, J =10.0 Hz, 1 H), 5.44 (s, 1 H), 5.33 (d, J = 7.4 Hz, 1 H), 5.12 (s, 1 H), 5.00-5.08 (m, 3 H), 4.90-4.95 (m, 3 H), 4.72-4.77 (m, 3 H), 4.68 (d, J = 11.4 Hz, 1 H), 4.53-4.60 (m, 3 H), 4.36-4.50 (m, 5 H)H), 4.17-4.27 (m, 6 H), 4.03-4.12 (m, 5 H), 3.93-3.99 (m, 2 H), 3.80-3.90 (m, 3 H), 3.65-3.69 (m, 1 H), 3.55-3.62 (m, 4 H), 3.42-3.47 (m, 2 H), 3.32-3.40 (m, 3 H), 3.19 (d, J = 9.8 Hz, 1 H), 2.71-2.81 (m, 2 H), 2.13 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.91 (s, 3 H, Ac); ¹³C NMR (CDCl₃, 100 MHz): δ170.7, 170.2, 169.3, 167.7, 138.9, 138.8, 138.7, 138.5, 138.3 (2 C), 137.9 (2 C), 137.2, 134.1, 133.9, 133.5, 131.7, 130.3, 129.1, 128.8, 128.6 (2 C), 128.4 (2 C), 128.3, 128.1 (2 C), 127.9, 127.8, 127.7 (3 C), 127.6, 127.5 (2 C), 127.4, 127.1, 127.0, 126.9, 123.1, 102.3, 100.9, 97.5, 97.2 (2 C), 95.3, 78.9, 78.2 (2 C), 77.8, 77.4, 76.6, 76.0, 75.2, 74.9, 74.6, 74.5, 74.4, 74.0, 73.2, 72.9, 72.7, 72.1, 71.8, 71.0, 70.8, 70.6, 70.4, 68.7, 68.2, 67.7, 66.4, 61.3, 56.5, 55.8, 54.2, 20.8 (2 C), 20.6; MALDI-MS: [M+Na]+ C₁₃₀H₁₂₅N₃O₃₂Na calcd for 2262.8144, found 2262.7908

Benzyl 3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tri-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 3)$ -2,4-O-di-benzyl- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-ph



The compound **17** (350 mg, 0.156 mmol) was treated accordingly to the general procedure **B** to afford pentasaccharide acceptor **18** (326 mg, 93%). $[\alpha]_D^{20}$ 20.9 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ 7.91-7.93 (m, 1 H), 7.60-7.80 (m, 10 H), 7.45-7.59 (m, 8 H), 7.20-7.43 (m, 26 H), 7.14-7.18 (m, 2 H), 7.00-7.10 (m, 7 H), 6.90-7.00 (m, 5 H), 6.77-6.85 (m, 3 H), 5.65 (t, *J* = 10.0 Hz, 1 H), 5.33 (d, *J* = 7.2 Hz, 1 H), 5.19 (d, *J* = 8.3 Hz, 1 H), 5.11 (d, *J* = 11.6 Hz, 1 H), 5.09 (d, *J* = 9.5 Hz, 1 H), 5.03 (d, *J* = 7.6 Hz, 1 H), 5.00 (d, *J* = 12.3 Hz, 1 H), 4.95 (d, *J* = 12.0 Hz, 1 H), 4.92 (d, *J* = 9.8 Hz, 1 H), 4.88 (d, *J* = 11.8 Hz, 1 H), 4.73-4.79 (m, 2 H), 4.63-4.69 (m, 2 H), 4.52-4.62 (m, 5 H), 4.50 (d, *J* = 4.5 Hz, 1 H), 4.40-4.47 (m, 3 H), 4.34-4.36 (m, 1 H), 4.22-4.30 (m, 5 H), 4.12-4.21 (m, 2 H), 4.02-4.10 (m, 3 H), 3.96-4.01 (m, 2 H), 3.87-3.93 (m, 2 H), 3.70-3.77 (m, 2 H), 3.66-3.68 (m, 1 H), 3.57-3.62 (m, 3 H), 3.46-3.53 (m, 3 H), 3.32-3.43 (m, 4 H), 3.22 (d, *J* = 9.6 Hz, 1 H), 2.76-2.83 (m, 2 H), 2.38-2.42 (m, 1 H), 2.10 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 1.90 (s, 3 H, Ac); ¹³C NMR (CDCl₃, 100 MHz): δ 170.7, 170.2, 169.4, 167.7, 138.8 (2 C), 138.7 (2 C), 138.5, 138.1, 137.9, 137.2, 134.1, 134.0, 133.5, 131.7, 131.5, 129.0, 128.8, 128.5, 128.4, 128.3 (2 C), 126.0, 123.1, 100.3, 98.4, 97.3, 97.2, 95.7, 80.1, 78.3, 77.8, 77.4, 76.2, 75.1,

74.9, 74.8 (2 C), 74.6 (2 C), 74.3, 74.2, 73.0, 72.8, 71.4, 71.1, 70.6, 70.5, 70.4, 68.7, 68.2, 67.7, 61.6, 56.5, 55.8, 54.3, 20.8, 20.7, 20.6; MALDI-MS: [M+Na]+ C₁₃₀H₁₂₇N₃O₃₂Na calcd for 2264.8300, found 2264.8450

Benzyl 3,4,6-O-tri-acetyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tribenzyl- α -D-Mannopyranosyl- $(1\rightarrow 3)$ -[3,4,6-O-tri-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 2)$ -3,4,6-O-tri-benzyl- α -D-Mannopyranosyl- $(1\rightarrow 6)$]-2,4-O-di-benzyl- β -D-Mannopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-glucopyranosyl- $(1\rightarrow 4)$ -3,6-O-di-benzyl-2-deoxy-phthalimido- β -D-di-benzyl-2-deoxy-phthalimido- β -D-di-benzyl-2-deoxy-phthalimido-



Compound 18 (400 mg, 0.178 mmol) was glycosylated with 3 (245 mg, 0.232 mmol) by following general procedure A to get the desired α anomer 19 (391 mg, 68%) and β anomer 19' (98 mg, 17%) as colorless oil. $[\alpha]_{D}^{20}$ 15.4 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 500 MHz): δ 7.88-7.90 (m, 1 H), 7.68-7.81 (m, 6 H), 7.55-7.65 (m, 5 H), 7.15-7.50 (m, 60 H), 6.95-7.10 (m, 13 H), 6.85-6.95 (m, 5 H), 6.75-6.85 (m, 3 H), 6.70-6.74 (m, 2 H), 6.62-6.64 (m, 1 H), 5.56 (t, J = 9.7 Hz, 1 H), 5.29 (s, 1 H), 5.25 (d, J = 7.0 Hz, 1 H), 5.07-5.12 (m, 2 H), 4.98-5.06 (m, 3 H), 4.85-4.95 (m, 5 H), 4.75-4.85 (m, 3 H), 4.67-4.76 (m, 6 H), 4.47-4.65 (m, 8 H), 4.32-4.45 (m, 9 H), 4.13-4.30 (m, 10 H), 3.93-4.09 (m, 7 H), 3.68-3.89 (m, 9 H), 3.46-3.61 (m, 8 H), 3.24-3.41 (m, 7 H), 3.15-3.19 (m, 2 H), 2.08 (s, 3 H, Ac), 2.07 (s, 3 H, Ac), 1.99 (s, 3 H, Ac); ¹³C NMR (CDCl₃, 125 MHz): δ173.2, 170.7, 170.2, 169.3, 168.1, 167.8, 167.5, 139.0, 138.9, 138.8, 138.7 (2 C), 138.5, 138.4, 138.3, 138.3, 138.1 (2 C), 138.0 (2 C), 137.2, 133.5, 131.8, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 128.3 (2 C), 128.2 (2 C), 128.1, 128.0 (2 C), 127.8 (2 C), 127.7, 127.6, 127.5 (2 C), 127.4, 127.3 (2 C), 127.2, 127.1, 126.9, 125.8, 123.1, 101.7 (*J*_{C H} = 158.4 Hz), 98.2 ($J_{C, H} = 171.1$ Hz), 97.8 ($J_{C, H} = 171.4$ Hz), 97.1 ($J_{C, H} = 165.7$ Hz, $J_{C, H} = 165.4$ Hz), 97.0 (*J*_{C,H} = 169.2 Hz), 95.4 (*J*_{C,H} = 165.6 Hz), 80.2, 79.6, 79.2, 79.1, 78.9, 77.9, 77.4, 77.0, 76.5, 75.9, 75.2, 74.9, 74.6 (2 C), 74.5, 74.4, 74.2 (2 C), 74.0, 73.6, 73.4, 73.3, 73.0, 72.8, 72.7, 72.5, 72.4, 72.3, 71.9, 71.3, 70.9, 70.5, 70.2, 69.7, 69.5, 68.8, 68.4, 68.1, 67.7, 66.8, 61.2, 60.4, 56.7, 55.8, 55.6, 54.3, 53.5, 21.1, 20.7, 20.5; MALDI-MS: [M+Na]+ C₁₉₂H₁₈₆N₄O₄₃Na calcd for 3258.2389, found 3258.4081

Benzyl 3,4,6-O-tri-acetyl-2-deoxy-phthalimido-β-D-glucopyranosyl-(1→2)-3,4,6-O-tribenzyl-α-D-Mannopyranosyl-(1→3)-[3,4,6-O-tri-benzyl-2-dexoy-phthalimido-β-Dglucopyranosyl-(1→2)-3,4,6-O-tri-benzyl-β-D-Mannopyranosyl-(1→6)]-2,4-O-di-benzyl-β-D-Mannopyranosyl-(1→4)-3,6-O-di-benzyl-2-dexoy-phthalimido-β-D-glucopyranosyl-(1→4)-3,6-O-di-benzyl-2-dexoy-phthalimido-β-D-glucopyranoside (19'): $[\alpha]_D^{20}$ 23.4 (c 1, CH₂Cl₂); ¹H NMR (CDCl₃, 400 MHz): δ7.50-7.75 (m, 18 H), 7.10-7.50 (m, 56 H), 6.95-7.10 (m, 9 H), 6.72-6.92 (m, 9 H), 6.60-6.70 (m, 4 H), 5.62 (t, *J* = 9.4 Hz, 1 H), 5.45 (d, *J* = 8.4 Hz, 1 H), 5.32 (d, *J* = 7.5 Hz, 1 H), 5.07-5.11 (m, 3 H), 4.96-5.04 (m, 4 H), 4.84-4.91 (m, 4 H), 4.75-4.79 (m, 3 H), 4.60-4.71 (m, 6 H), 4.32-4.54 (m, 14 H), 4.25-4.29 (m, 8 H), 3.89-4.06 (m, 8 H), 3.77-3.86 (m, 5 H), 3.66-3.72 (m, 3 H), 3.53-3.61 (m, 3 H), 3.36-3.50 (m, 7 H), 3.23-3.35 (m, 5 H), 3.11-3.19 (m, 2 H), 3.04-3.07 (m, 1 H), 2.95-3.00 (m, 2 H), 2.12 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 1.91 (s, 3 H, Ac); ¹³C NMR (CDCl₃, 100 MHz): δ 170.8, 170.2, 169.3, 168.4, 168.1, 167.8, 167.6, 167.2, 139.6, 139.2 (2 C), 138.9, 138.8, 138.7, 138.6 (3 C), 138.5, 138.2 (2 C), 137.5, 137.2, 133.8, 133.5, 133.4, 132.1, 131.8, 131.7, 131.5, 129.4, 129.1 (2 C), 129.0, 128.8, 128.6, 128.5, 128.4, 128.3, 128.2 (2 C), 127.1, 127.0, 126.8, 125.7, 123.5, 123.1, 122.7, 100.5 ($J_{C, H} = 158.9 \text{ Hz}$), 99.5 ($J_{C, H} = 159.6 \text{ Hz}$), 99.2 ($J_{C, H} = 169.8 \text{ Hz}$), 98.4 ($J_{C, H} = 172.1 \text{ Hz}$), 98.2 ($J_{C, H} = 167.4 \text{ Hz}$), 97.0 ($J_{C, H} = 166.6 \text{ Hz}$), 95.9 ($J_{C, H} = 169.9 \text{ Hz}$), 81.2, 79.8, 79.3, 79.1, 78.9, 78.6, 77.9, 77.8, 77.5, 77.3 (2 C), 76.7, 75.8, 75.1, 74.8, 74.6, 74.5, 74.3, 74.1, 74.0, 73.3, 73.2, 73.0 (2 C), 72.7, 72.5 (2 C), 71.6, 70.9, 70.7, 70.6, 70.5, 70.1, 69.7, 69.3, 68.6 (2 C), 67.9, 66.7, 61.5, 56.4, 56.2, 55.9, 54.3, 20.8, 20.7, 20.6; MALDI-MS: [M+Na]+ C₁₉₂H₁₈₆N₄O₄₃Na calcd for 3258.2389, found 3258.3048

3,4,6-O-tri-acetyl-2-deoxy-acetamido- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-Mannopyranosyl-(1 \rightarrow 3)-[2-deoxy-acetoamido- β -D-glucopyranosyl-(1 \rightarrow 2)- α -D-Mannopyranosyl-(1 \rightarrow 6)]- β -D-Mannopyranosyl-(1 \rightarrow 4)-2-deoxy-acetamido- β -D-glucopyranosyl-(1 \rightarrow 4)-2-deoxy-



Following the general procedure C and E, compound 19 (150 mg, 0.046 mmol) yielded the compound N210 (37 mg, 65% over three steps). $[\alpha]_D^{20}$ 7.9 (c 0.5, H₂O); ¹H NMR (D₂O, 500 MHz): $\delta 5.25$ (dd, J = 10.4, 9.4 Hz, 1 H), 5.17 (d, J = 2 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.12 (s, 1 H, Man2 H-1), 5.08 (t, J = 9.8 Hz, 1 H), 4.91 (s, 1 H, Man3 H-1), 4.81 (overlapped with D_2O_1 H, GlcNAc-4 H-1), 4.76 (s, 1 H, Man β H-1), 4.68 (d, J = 7.9 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.60 (d, J = 7.8 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.59 (d, J = 7.8 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.54 (d, J = 8.4 Hz, 1 H, GlcNAc-3 H-1), 4.40 (dd, J = 12.6, 3.5 Hz, 1 H, 4.23 (d, J = 1.3 Hz, 1 H, 4.21 (d, J = 1.5 Hz, 1 H, 4.19 -4.20 (m, 1 H), 4.10 (d, J = 1.5 Hz, 1 H, 4.19 -4.20 (m, 1 H), 4.10 (d, J = 1.5 Hz, 1 H)1.9 Hz, 1 H), 3.94-4.00 (m, 3 H), 3.84-3.92 (m, 7 H), 3.71-3.81 (m, 8 H), 3.66-3.70 (m, 3 H), 3.58-3.65 (m, 6 H), 3.45-3.54 (m, 4 H), 3.39-3.42 (m, 1 H), 2.11 (s, 3 H, Ac), 2.07 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.99 (s, 3 H, Ac); ¹³C NMR (D₂O, 125 MHz): δ174.7, 174.6, 174.5, 174.3, 173.6, 173.1, 172.7, 101.3 (GlcNAc-2 C-1), 100.3 (*J*_{CH} = 162.5 Hz, Manβ C-1), 99.5 (GlcNAc-3 C-1), 99.3 (*J*_{CH} = 172.1 Hz, Man2 C-1), 99.0 (GlcNAc-4 C-1), 96.9 (J_{CH} = 172.3 Hz, Man3 C-1), 94.7 (GlcNAc-1 C-1 of β anomer), 90.3 (GlcNAc-1 C-1 of α anomer), 80.3, 79.5, 79.4, 79.1, 76.8, 76.2, 75.7, 74.5, 74.3, 74.2, 73.5, 73.3, 72.7, 72.4, 72.2, 71.9, 71.1, 70.0, 69.9, 69.8, 69.5, 69.4, 69.2, 69.1, 68.4, 67.2, 67.1, 65.7, 65.6, 61.7, 61.5, 60.5, 60.0, 59.9, 59.8, 56.0, 55.2, 54.8, 53.5, 53.4, 22.2, 22.1, 22.0, 21.8, 19.9, 19.8;ESI-MS: [M+H]+ C₅₆H₉₁N₄O₃₉ calcd for 1443.5260, found 1443.5275

VII. HPLC profiles, MS and NMR data of purified N-glycans





ESI-MS, calculated: 1316.4865; found [M+2H]²⁺ 659.2510



MALDI-MS,; found [M+Na]⁺ 1339.509, [M+K]⁺ 1355.530

¹**H** NMR (D₂O, 500 MHz): δ 5.18 (d, J = 1.9 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.11 (s, 1 H, Man2 H-1), 4.92 (s, 1 H, Man3 H-1), 4.77 (s, 1 H, Manβ H-1), 4.69 (d, J = 7.9 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.61 (d, J = 7.7 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.59 (d, J = 7.7 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.55 (d, J = 8.4 Hz, 2 H, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.24 (d, J = 1.9 Hz, 1 H), 4.18 (d, J = 1.4 Hz, 1 H), 4.10 (d, J = 2.2 Hz, 1 H), 3.42-3.95 (m, 39 H), 2.07 (s, 3 H, Ac), 2.04 (s, 6 H, 2 Ac), 2.03 (s, 3 H, Ac)



HILIC-ELSD, $T_R = 15.65$ min



ESI-MS, calculated: 1640.5922; found [M+2H]²⁺ 821.3046



MALDI-MS, found [M+Na]⁺ 1663.552, [M+K]⁺ 1679.502

¹**H** NMR (D₂O, 500 MHz): δ 5.19 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.12 (s, 1 H, Man2 H-1), 4.93 (s, 1 H, Man3 H-1), 4.77 (s, 1 H, Manβ H-1), 4.70 (d, J = 7.5 Hz, 0.4 H, GlcNAc-1 of β anomer), 4.57-4.62 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.48 (d, J = 7.6 Hz, 1 H, Gal-1 H-1), 4.47 (d, J = 7.6 Hz, 1 H, Gal-2 H-1), 4.26 (brs, 1H), 4.19 (brs, 1 H), 4.11 (brs, 1 H), 3.47-4.00 (m, 51 H), 2.09 (s, 3 H, Ac), 2.05 (s, 6 H, 2 Ac), 2.04 (s, 3 H, Ac)



HILIC-ELSD, $T_R = 18.22$ min



ESI-MS, calculated: 2222.7830; found [M+2H]²⁺ 1112.4028



¹**H NMR** (D₂O, 500 MHz): δ 5.17 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.10 (s, 1 H, Man2 H-1), 4.77-5.00 (overlapped with D₂O, 1 H, Man3 H-1), 4.75 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.8 Hz, 0.4 H, GlcNAc-1 of β anomer), 4.52-4.61 (m, 5 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1, Gal-1 H-1, Gal-2 H-1), 4.24 (s, 1 H), 4.18 (s, 1 H), 4.08-4.12 (m, 3 H), 3.45-4.00 (m, 63 H), 2.75 (m, J = 12.4, 3.5 H, 2 H, Neu5Ac H-3e), 2.07 (s, 3 H, Ac), 2.03 (s, 9 H, 3 Ac), 2.03 (s, 6 H, 2 Ac), 1.79 (t, J = 12.4 Hz, 2 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 20.17 \text{ min}$





¹**H NMR** (D₂O, 500 MHz): δ 5.19 (brs, 0.7 H, GlcNAc-1 H-1 of α anomer), 5.13 (s, 1 H, Man2 H-1), 4.95 (s, 1 H, Man3 H-1), 4.76-4.94 (overlapped with D₂O, 1 H, Manβ H-1), 4.69 (d, J = 7.2 Hz, 0.3 H, GlcNAc-1 of β anomer), 4.59-4.65 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.44 (d, J = 7.2 Hz, 2 H, Gal-1 H-1, Gal-2 H-1), 4.26 (s, 1 H), 4.20 (s, 1 H), 4.12 (s, 1 H), 3.48-4.01 (m, 65 H), 2.65-2.69 (m, 2 H, Neu5Ac H-3e), 2.08 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.03 (s, 9 H, 3 Ac), 1.72 (m, 2 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 19.38$ min



ESI-MS, calculated: 1932.7080; found [M+2H]²⁺ 967.3640



MALDI-MS, found [M+Na]⁺ 1955.757, [M+K]⁺ 1971.753

¹**H NMR** (D₂O, 500 MHz): δ 5.20 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.13-5.15 (m, 2 H, Fuc-1 H-1, Fuc-2 H-1), 5.12 (s, 1 H, Man2 H-1), 4.93 (s, 1 H, Man3 H-1), 4.75-4.87 (overlapped with D₂O, 1 H, Manβ H-1), 4.71 (d, J = 7.5 Hz, 0.4 H, GlcNAc-1 of β anomer), 4.58-4.63 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.45-4.47 (m, 2 H, Gal-1 H-1, Gla-2 H-1), 4.21 (brs, 1 H), 4.20 (brs, 1 H), 4.12 (brs, 1 H), 3.46-4.03 (m, 59 H), 2.10 (s, 3 H, Ac), 2.06 (s, 9 H, 3 Ac), 1.17-1.22 (m, 6 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 21.28$ min



ESI-MS, calculated: 2514.8988; found [M+2H]²⁺ 1258.9621, [M+3H]³⁺ 839.6437



¹**H NMR** (D₂O, 500 MHz): δ4.75-5.15 (overlapped with D₂O, 6 H, Man5 H-1, Man4 H-1, Man3 H-1, Man2 H-1, Manβ H-1, GlcNAc-1 H-1), 4.55-4.62 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.50-4.53 (m, 2 H, Gal-1 H-1, Gal-2 H-1), 4.24-4.26 (m, 1 H), 4.18-4.20 (m, 2 H), 4.08-4.10 (m, 4 H), 3.45-4.03 (m, 69 H), 2.74-2.79 (m, 2 H, Neu5Ac H-3e), 2.09 (s, 3 H, Ac), 2.04 (s, 6 H, 2 Ac), 2.03 (s, 9 H, 3 Ac), 1.77-1.82 (m, 2 H, Neu5Ac H-3a), 1.15-1.19 (m, 6 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 14.86 \text{ min}$



ESI-MS, calculated: 1437.5128; found [M+2H]²⁺ 719.7645



MALDI-MS, found [M+Na]⁺ 1460.564, [M+K]⁺ 1476.516

NMR data listed in Part VI



HILIC-ELSD, $T_R = 16.79$ min



ESI-MS, calculated: 1599.5656; found [M+2H]²⁺ 800.7887



MALDI-MS, found [M+Na]⁺ 1622.504, [M+K]⁺ 1638.478

¹**H** NMR (D₂O, 500 MHz): δ 5.24 (s, 1 H, Man5 H-1), 5.19 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.11 (s, 1 H, Man2 H-1), 4.94 (s, 1 H, Man3 H-1), 4.89 (s, 1 H, Man4 H-1), 4.77-4.88 (overlapped with D₂O, 1 H, Manβ H-1), 4.69 (d, J = 7.6 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.57-4.61 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.46 (d, J = 7.7 Hz, 1 H, , Gal H-1), 4.25 (brs, 1 H), 4.21 (brs, 1 H), 4.05 (s, 1 H), 3.48-4.02 (m, 51 H), 2.08 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 2.04 (s, 3 H, Ac)


HILIC-ELSD, $T_R = 17.93$ min



ESI-MS, calculated: 1890.6610; found [M+2H]²⁺ 946.3386



MALDI-MS, found [M-H]⁻ 1889.568

¹**H NMR** (D₂O, 500 MHz): δ 5.23 (s, 1 H, Man5 H-1), 5.18 (brs, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.10 (s, 1 H, Man2 H-1), 4.93 (s, 1 H, Man3 H-1), 4.77-4.92 (overlapped with D₂O, 2 H, Man4 H-1, Manβ H-1), 4.68 (d, J = 7.8 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.52-4.61 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, Gal H-1), 4.24 (brs, 1 H), 4.20 (brs, 1 H), 4.10 (dd, J = 9.8, 2.1 Hz, 1 H), 3.45-4.05 (m, 58 H), 2.75 (dd, J = 12.2, 4.2 Hz, 1 H, Neu5Ac H-3e), 2.07 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.79 (t, J = 12.2 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 19.09 \text{ min}$



ESI-MS, calculated: 1890.6610; found [M+2H]²⁺ 946.3099



MALDI-MS, found [M-H]⁻ 1889.632

¹**H** NMR (D₂O, 500 MHz): δ 5.20 (s, 1 H, Man5 H-1), 5.15 (brs, 0.7 H, GlcNAc-1 H-1 of α anomer), 5.09 (s, 1 H, Man2 H-1), 4.90 (s, 1 H, Man3 H-1), 4.85 (s, 1 H, Man4 H-1), 4.75 (s, 1 H, Manβ H-1), 4.66 (d, J = 7.8 Hz, 0.3 H, GlcNAc-1 H-1 of β anomer), 4.55-4.57 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.40 (d, J = 7.6 Hz, 1 H, Gal H-1), 4.21 (brs, 1 H), 4.17 (brs, 1 H), 4.01 (s, 1 H), 3.45-3.96 (m, 58 H), 2.62 (dd, J = 12.3, 4.3 Hz, 1 H, Neu5Ac H-3e), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 3 H, Ac), 1.68 (t, J = 12.3 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 18.59$ min



ESI-MS, calculated: 1745.6235; found [M+2H]²⁺ 873.8209



MALDI-MS, found [M+Na]⁺ 1768.682, [M+K]⁺ 1784.669

¹**H** NMR (D₂O, 500 MHz): δ 5.23 (s, 1 H, Man5 H-1), 5.17 (brs, 0.7 H, GlcNAc-1 H-1 of α anomer), 5.11 (d, J = 3.6 Hz, 1 H, Fuc H-1), 5.09 (s, 1 H, Man2 H-1), 4.94 (s, 1 H, Man3 H-1), 4.89 (s, 1 H, Man4 H-1), 4.79-4.85 (overlapped with D₂O, 1 H, Manβ H-1), 4.69 (d, J = 7.4 Hz, 0.3 H, GlcNAc-1 H-1 of β anomer), 4.57-4.61 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.43 (d, J = 7.7 Hz, 1 H, Gal H-1), 4.24 (brs, 1 H), 4.19 (s, 1 H), 4.04 (brs, 1 H), 3.44-4.00 (m, 55 H), 2.07 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.16 (d, J = 6.4 Hz, 3 H, Fuc-CH₃)







ESI-MS, calculated: 2036.7189; found [M+2H]²⁺ 1019.3699



MALDI-MS, found [M-H]⁻ 2035.534

¹**H** NMR (D₂O, 500 MHz): δ 5.13 (d, J = 0.8 Hz, 1 H, Man5 H-1), 5.08 (d, J = 2.0 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.01 (d, J = 3.9 Hz, 1 H, Fuc H-1), 4.99 (s, 1 H, Man2 H-1), 4.84 (s, 1 H, Man3 H-1), 4.69 (d, J = 1.6 Hz, 1 H, Man4 H-1), 4.68 (s, 1 H, Manβ H-1), 4.59 (d, J = 7.9 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.47-4.52 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.40 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.14 (d, J = 2.1 Hz, 1 H), 4.08-4.10 (m, 1 H), 3.36-4.00 (m, 63 H), 2.66 (dd, J = 12.3, 4.5 Hz, 1 H, Neu5Ac H-3e), 2.01 (s, 3 H, Ac), 1.94 (s, 3 H, Ac), 1.93 (s, 3 H, Ac), 1.92 (s, 3 H, Ac), 1.69 (t, J = 12.3 Hz, 1 H, Neu5Ac H-3e), 1.06 (d, J = 6.6 Hz, 3 H, Fuc-CH₃)





ESI-MS, calculated: 951.3543; found [M+H]⁺ 952.3630

MALDI-MS, found [M+Na]⁺ 974.622, [M+K]⁺ 990.629



NMR data listed in Part VI







ESI-MS, calculated: 1113.4072; found [M+H]⁺ 1114.4144

MALDI-MS, found [M+Na]⁺ 1136.451, [M+K]⁺ 1152.342



¹**H** NMR (D₂O, 500 MHz): δ 5.17 (d, J = 2.5 Hz, 0.7 H, GlcNAc-1 H-1 of α anomer), 5.11 (s, 1 H, Man2 H-1), 4.77 (s, 1 H, Manβ H-1), 4.68 (d, J = 8.0 Hz, 0.3 H, GlcNAc-1 H-1 of β anomer), 4.59 (d, J = 7.8 Hz, 0.7 H, GlcNAc-2 H-1 of α anomer), 4.58 (d, J = 7.6 Hz, 0.3 H, GlcNAc-2 H-1 of β anomer), 4.56 (d, J = 7.7 Hz, 1 H, GlcNAc-3 H-1), 4.45 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.22 (d, J = 3.0 Hz, 1 H), 4.18 (dd, J = 3.3, 1.4 Hz, 1 H), 3.43-3.98 (m, 34 H), 2.05 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac)







ESI-MS, calculated: 1404.5026; found [M+2H]²⁺ 703.2563

MALDI-MS, found [M-H]⁻ 1403.409



¹**H** NMR (D₂O, 500 MHz): δ5.18 (d, J = 2.4 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.11 (s, 1 H, Man2 H-1), 4.77 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.7 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.59 (d, J = 7.6 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.58 (d, J = 7.2 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.55 (d, J = 7.8 Hz, 1 H, GlcNAc-3 H-1), 4.53 (d, J = 8.0 Hz, 1 H, Gal H-1), 4.22 (d, J = 2.5 Hz, 1 H), 4.18 (d, J = 2.9 Hz, 1 H), 4.11 (dd, J = 9.9, 2.9 Hz, 1 H), 3.81-4.00 (m, 12 H), 3.53-3.80 (m, 25 H), 3.43-3.52 (m, 3 H), 2.75 (dd, J = 12.4, 4.7 Hz, 1 H, Neu5Ac H-3e), 2.06 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.79 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 13.27$ min



ESI-MS, calculated: 1404.5026; found [M+2H]²⁺ 703.2563

MALDI-MS, found [M-H]⁻ 1403.346



¹**H** NMR (D₂O, 500 MHz): δ 5.17 (d, J = 2.7 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.13 (s, 1 H, Man2 H-1), 4.77 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.9 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.57-4.60 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.43 (d, J = 7.9 Hz, 1 H, Gal H-1), 4.22 (d, J = 2.7 Hz, 1 H), 4.18 (d, J = 2.0 Hz, 1 H), 3.46-4.01 (m, 41 H), 2.65 (dd, J = 12.4, 4.7 Hz, 1 H, Neu5Ac H-3e), 2.06 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.99 (s, 3 H, Ac), 1.71 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a)





ESI-MS, calculated: 1259.4651; found [M+2H]²⁺ 630.7370

MALDI-MS, found [M+Na]⁺ 1282.378



¹**H** NMR (D₂O, 500 MHz): δ 5.17 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.11 (d, J = 4.0 Hz, 1 H, Fuc H-1), 5.10 (s, 1 H, Man2 H-1), 4.77 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.8 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.56-4.60 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.43 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.22 (d, J = 2.8 Hz, 1 H), 4.17 (d, J = 2.0 Hz, 1 H), 3.83-4.02 (m, 12 H), 3.53-3.80 (m, 22 H), 3.43-3.49 (m, 4 H), 2.05 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.16 (d, J = 6.6 Hz, 3 H, Fuc-CH₃)





ESI-MS, calculated: 1550.5605; found [M+2H]²⁺ 776.2854



MALDI-MS, found [M-H]⁻ 1549.451

¹**H** NMR (D₂O, 500 MHz): δ 5.18 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.10 (s, 1 H, Man2 H-1), 4.79-4.95 (overlapped with D₂O, 1 H, Man3 H-1), 4.77 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.0 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.55-4.60 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.50 (d, J = 7.5 Hz, 1 H, Gal H-1), 4.22 (brs, 1 H), 4.18 (m, 1 H), 3.45-4.03 (m, 44 H), 2.75 (dd, J = 12.4, 3.8 Hz, 1 H, Neu5Ac H-3e), 2.06 (s,3 H, Ac), 2.03 (s, 9 H, 3 Ac), 1.79 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a), 1.16 (d, J = 5.4 Hz, 3 H, Fuc-CH₃).



HILIC-ELSD, $T_R = 10.71$ min



ESI-MS, calculated: 1113.4072; found [M+H]⁺ 1114.4170



MALDI-MS, found [M+Na]⁺ 1136.316, [M+K]⁺ 1152.325

NMR data listed in Part VI





ESI-MS, calculated: 1275.4600; found [M+2H]²⁺ 638.7382



MALDI-MS, found [M+Na]⁺ 1298.565, [M+K]⁺ 1314.668

¹**H** NMR (D₂O, 500 MHz): δ 5.18 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.11 (s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.77-4.82 (overlapped with D₂O, 1 H, Manβ H-1), 4.68 (d, J = 7.9 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.60 (d, J = 7.8 Hz, 1 H, GlcNAc-2 H-1 of α anomer), 4.59 (d, J = 7.8 Hz, 1 H, GlcNAc-2 H-1 of β anomer), 4.56 (d, J = 6.8 Hz, 1 H, GlcNAc-3 H-1), 4.46 (d, J = 6.7 Hz, 1 H, Gal H-1), 4.25 (brs, 1 H), 4.18 (brs, 1 H), 3.96-3.98 (m, 2 H), 3.47-3.95 (m, 38 H), 2.07 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac)



HILIC-ELSD, $T_R = 14.26$ min



ESI-MS, calculated: 1566.5554; found [M+2H]²⁺ 784.2826



MALDI-MS, found [M-H]⁻ 1565.540

¹**H** NMR (D₂O, 500 MHz): δ 5.18 (d, J = 1.5 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.11 (s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.77-4.85 (overlapped with D₂O, 1 H, Manβ H-1), 4.69 (d, J = 7.9 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.53-4.61 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, Gal H-1), 4.25 (brs, 1 H), 4.18 (brs, 1 H), 4.09-4.12 (m, 1 H), 3.47-4.02 (m, 46 H), 2.75 (dd, J = 12.4, 4.6 Hz, 1 H, Neu5Ac H-3e), 2.07 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.79 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 15.37$ min



ESI-MS, calculated: 1566.5554; found [M+2H]²⁺ 784.2845



MALDI-MS, found [M-H]⁻ 1565.516

¹**H NMR** (D₂O, 500 MHz): δ 5.17 (d, J = 2.5 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.12 (s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.77 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.9 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.58-4.61 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.43 (d, J = 8.0 Hz, 1 H, Gal H-1), 4.24 (d, J = 2.2 Hz, 1 H), 4.18-4.19 (m, 1 H), 3.95-4.01 (m, 3 H), 3.47-3.92 (m, 46 H), 2.65 (dd, J = 12.4, 4.7 Hz, 1 H, Neu5Ac H-3e), 2.07 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.71 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a)







ESI-MS, calculated: 1421.5179; found [M+2H]²⁺ 711.7661



MALDI-MS, found [M+Na]⁺ 1444.630, [M+K]⁺ 1460.599

¹**H** NMR (D₂O, 500 MHz): δ 5.20 (d, J = 2.2 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.15 (d, J = 3.9 Hz, 1 H, Fuc H-1), 5.13 (s, 1 H, Man2 H-1), 4.94 (s, 1 H, Man3 H-1), 4.79-4.83 (overlapped with D₂O, 1.5 H, GlcNAc-1 H-1 of β anomer, Manβ H-1), 4.60-4.64 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.46 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.28 (brs, 1 H), 4.19-4.21 (m, 1 H), 3.47-4.03 (m, 44 H), 2.10 (s, 3 H, Ac), 2.07 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 1.19 (d, J = 6.6 Hz, 3 H, Fuc-CH₃)







ESI-MS, calculated: 1712.6133; found [M+2H]²⁺ 857.3162



MALDI-MS, found [M-H]- 1711.522

¹**H** NMR (D₂O, 500 MHz): δ 5.14 (d, J = 1.5 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.05-5.07 (m, 2 H, Fuc H-1, Man2 H-1), 4.87 (s, 1 H, Man3 H-1), 4.73 (s, 1 H, Manβ H-1), 4.64 (d, J = 7.2 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.52-4.56 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.46 (d, J = 7.4 Hz, 1 H, Gal H-1), 4.20-4.22 (m, 2 H), 4.12-4.14 (m, 2 H), 4.03-4.06 (m, 2 H), 3.41-3.95 (m, 47 H), 2.71 (dd, J = 12.1, 3.7 Hz, Neu5Ac H-3e), 2.03 (s, 3 H), 1.99 (s, 9 H, 3 Ac), 1.75 (t, J = 12.1 Hz, 1 H, Neu5Ac H-3a), 1.11 (d, J = 6.1 Hz, 3 H, Fuc-CH₃)





ESI-MS, calculated: 951.3543; found [M+H]⁺ 952.3555

MALDI-MS, found [M+Na]⁺ 974.271, [M+K]⁺ 990.268



NMR data listed in Part VI





ESI-MS, calculated: 1113.4072; found [M+H]⁺ 1114.4109

MALDI-MS, found [M+Na]⁺ 1136.458, [M+K]⁺ 1152.442



¹**H** NMR (D₂O, 500 MHz): δ 5.14 (d, J = 2.0 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 4.87 (s, 1 H, Man2 H-1), 4.72 (s, 1 H, Manβ H-1), 4.64 (d, J = 7.7 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.56 (d, 1 H, GlcNAc-2 H-1 of α anomer), 4.55 (d, 1 H, GlcNAc-2 H-1 of β anomer), 4.53 (d, J = 8.2 Hz, 1 H, GlcNAc-3 H-1), 4.42 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.03-4.06 (m, 2 H), 3.41-3.95 (m, 40 H), 2.04 (s, 3 H, Ac), 2.00 (s, 3 H), 1.99 (s, 3 H, Ac).





ESI-MS, calculated: 1404.5026; found [M+2H]²⁺ 703.2563

MALDI-MS, found [M-H]⁻ 1403.442



¹**H** NMR (D₂O, 500 MHz): δ 5.12 (d, J = 1.8 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 4.86 (s, 1 H, Man2 H-1), 4.69 (s, 1 H, Manβ H-1), 4.63 (d, J = 7.9 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.48-4.55 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, Gal H-1), 4.01-4.06 (m, 3 H), 3.39-3.94 (m, 40 H), 2.69 (dd, J = 12.4, 3.0 Hz, 1 H, Neu5Ac H-3e), 2.02 (s, 3 H, Ac), 1.97 (s, 6 H, 2 Ac), 1.96 (s, 3 H, Ac), 1.74 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a)

min





ESI-MS, calculated: 1404.5026; found [M+2H]²⁺ 703.2565

MALDI-MS, found [M-H]⁻ 1403.427



¹**H** NMR (D₂O, 500 MHz): δ 5.14 (d, J = 2.3 Hz, 0.7 H, GlcNAc-1 H-1 of α anomer), 4.90 (s, 1 H, Man2 H-1), 4.73 (s, 1 H, Manβ H-1), 4.65 (d, J = 7.6 Hz, 0.3 H, GlcNAc-1 H-1 of β anomer), 4.53-4.57 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.40 (d, J = 7.9 Hz, 1 H, Gal H-1), 4.04-4.07 (m, 1 H), 4.02-4.04 (m, 1 H), 3.92-3.97 (m, 2 H), 3.43-3.90 (m, 39 H), 2.62 (dd, J = 12.4, 4.6 Hz, 1 H, Neu5Ac, H-3e), 2.04 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.99 (s, 3 H, Ac), 1.98 (s, 3 H, Ac), 1.68 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 12.34$ min

N044



ESI-MS, calculated: 1259.4651; found [M+2H]²⁺ 630.7381



MALDI-MS, found [M+Na]⁺ 1282.577

¹**H** NMR (D₂O, 500 MHz): δ 5.14 (d, J = 1.7 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.08 (d, J = 3.7 Hz, 1 H, Fuc H-1), 4.87 (s, 1 H, Man2 H-1), 4.72 (s, 1 H, Manβ H-1), 4.64 (d, J = 7.8 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.52-4.57 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.40 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.03-4.06 (m, 2 H), 3.38-3.96 (m, 38 H), 2.04 (s, 3 H, Ac), 1.99 (s, 6 H), 1.13 (d, J = 6.5 Hz, 3 H, Fuc-CH₃)







ESI-MS, calculated: 1550.5605; found [M+2H]²⁺ 776.2882



MALDI-MS, found [M-H]⁻ 1549.565

¹**H** NMR (D₂O, 500 MHz): δ5.15 (d, J = 2.6 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.08 (d, J = 3.9 Hz, 1 H, Fuc H-1), 4.88 (s, 1 H, Man2 H-1), 4.73 (s, 1 H, Manβ H-1), 4.66 (d, J = 7.9 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.57 (d, J = 7.7 Hz, 0.5 H, GlcNAc-2 H-1 of α anomer), 4.56 (d, J = 7.7 Hz, 0.5 H, GlcNAc-2 H-1 of β anomer), 4.54 (d, J = 8.2 Hz, 1 H, H-1, GlcNAc-3 H-1), 4.48 (d, J = 7.8 Hz, 1 H, H-1, Gal H-1), 4.06 (d, J = 2.8 Hz, 1 H), 4.04 (d, J = 2.4 Hz, 1 H), 3.40-3.98 (m, 45 H), 2.72 (dd, J = 12.5, 4.6 Hz, Neu5Ac H-3e), 2.04 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 3 H, Ac), 1.76 (t, J = 12.1 Hz, 1 H, Neu5Ac H-3a), 1.13 (d, J = 6.6 Hz, Fuc-CH₃).





ESI-MS, calculated: 1113.4072; found [M+H]⁺ 1114.4105



MALDI-MS, found [M+Na]⁺ 1136.299; [M+K]⁺ 1152.275

NMR data listed in Part VI



HILIC-ELSD, $T_R = 12.63$ min



ESI-MS, calculated: 1275.4600; found [M+2H]²⁺ 638.7374



MALDI-MS, found [M+Na]⁺ 1298.388, [M+K]⁺ 1314.366

¹**H** NMR (D₂O, 500 MHz): δ 5.15 (d, J = 2.2 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.06 (s, 1 H, Man2 H-1), 4.89 (s, 1 H, Man3 H-1), 4.73 (s, 1 H, Manβ H-1), 4.65 (d, J = 7.8 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.57 (d, J = 7.8 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.56 (d, J = 7.8 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.54 (d, J = 8.3 Hz, 1 H, GlcNAc-3, H-1), 4.43 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.22 (s, 1 H), 4.06-4.08 (m, 1 H), 4.01-4.03 (m, 1 H), 3.41-3.95 (m, 39 H), 2.04 (s, 3 H, Ac), 2.01 (s, 3 H, Ac), 2.00 (s, 3 H, Ac)





ESI-MS, calculated: 1566.5554; found [M+2H]²⁺ 784.2828



MALDI-MS, found [M-H]⁻ 1565.443

¹**H NMR** (D₂O, 500 MHz): δ 5.14 (d, J = 1.8 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.05 (s, 1 H, Man2 H-1), 4.88 (s, 1 H, Man3 H-1), 4.72 (s, 1 H, Manβ H-1), 4.65 (d, J = 7.6 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.50-4.57 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3, Gal H-1), 4.21 (brs, 1 H), 4.06-4.08 (m, 2 H), 4.01-4.03 (m, 1 H), 3.41-3.96 (m, 45 H), 2.71 (d, J = 12.4, 4.7 Hz, 1 H, Neu5NAc H-3e), 2.04 (s, 3 H, Ac), 1.99 (s, 6 H, 2 Ac), 1.98 (s, 3 H, Ac), 1.76 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a).



HILIC-ELSD, $T_R = 15.28$ min



ESI-MS, calculated: 1566.5554; found [M+2H]²⁺ 784.2882



MALDI-MS, found [M-H]⁻ 1565.437

¹**H NMR** (D₂O, 500 MHz): δ 5.14 (d, J = 2.2 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.06 (s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.74 (s, 1 H, Manβ H-1), 4.65 (d, J = 7.8 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.55-4.58 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.41 (d, J = 7.9 Hz, 1 H, Gal H-1), 4.08 (s, 1 H), 4.07-4.09 (m, 1 H), 4.02-4.04 (m, 1 H), 3.43-3.97 (m, 46 H), 4.63 (dd, J = 12.6, 4.6 Hz, 1 H, Neu5Ac H-3e), 2.04 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 3 H, Ac), 1.68 (t, J = 12.6 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 14.50$ min



ESI-MS, calculated: 1421.5179; found [M+2H]²⁺ 711.7671



MALDI-MS, found [M+Na]⁺ 1444.521, [M+K]⁺ 1460.499

¹**H** NMR (D₂O, 500 MHz): δ 5.14 (d, J = 2.0 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.09 (d, J = 3.7 Hz, Fuc H-1), 5.05 (s, 1 H, Man2 H-1), 4.87 (s, 1 H, Man3 H-1), 4.73 (s, 1 H, Manβ H-1), 4.65 (d, J = 7.1 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.53-4.57 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.40 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.22 (brs, 1 H), 4.05-4.07 (m, 1 H), 4.01-4.03 (m, 1 H), 3.40-3.96 (m, 43 H), 2.04 (s, 3 H, Ac), 1.99 (s, 6 H, 2 Ac), 1.13 (d, J = 6.5 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 15.97$ min



ESI-MS, calculated: 1712.6133; found [M+2H]²⁺ 857.3152



MALDI-MS, found [M-H]- 1711.599

¹**H** NMR (D₂O, 500 MHz): δ 5.19 (d, J = 2.2 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.13 (d, J = 3.8 Hz, 1 H, Fuc H-1), 5.10 (s, 1 H, Man2 H-1), 4.92 (s, 1 H, Man3 H-1), 4.79-4.87 (overlapped with D₂O, 1 H, Manβ H-1), 4.70 (d, J = 7.4 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.57-4.62 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.52 (d, J = 7.7 Hz, Gal H-1), 4.21 (brs, 1 H), 4.07-4.11 (m, 3 H), 3.45-4.02 (m, 49 H), 2.77 (dd, J = 12.3, 4.4 Hz, 1 H, Neu5Ac H-3e), 2.09 (s, 3 H, Ac), 2.04 (s, 9 H, 3 Ac), 1.80 (t, J = 12.3 Hz, Neu5Ac H-3a), 1.17 (d, J = 6.5 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 6.06 \text{ min}$



ESI-MS, calculated: 1442.5182; found [M+2H]²⁺ 722.2688



MALDI-MS, found [M+Na]⁺ 1465.291

NMR data listed in Part VI



HILIC-ELSD, $T_R = 13.65$ min



ESI-MS, calculated: 1478.5393; found [M+2H]²⁺ 740.2793



MALDI-MS, found [M+Na]⁺ 1501.574

¹**H NMR** (D₂O, 500 MHz): δ 5.18 (d, J = 1.9 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.11 (s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.76 (s, 1 H, Manβ H-1), 4.69 (d, J = 8.0 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.60 (d, J = 7.6 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.59 (d, J = 7.5 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.57 (d, J = 7.7 Hz, 1 H, GlcNAc-3, H-1), 4.54 (d, J = 8.4 Hz, 1 H, GlcNAc-4 H-1), 4.46 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.24 (d, J = 1.4 Hz, 1 H), 4.18-4.19 (m, 1 H), 4.09-4.10 (m, 1 H), 3.40-3.97 (m, 45 H), 2.07 (s, 3 H, Ac), 2.04 (s, 6 H, 2 Ac), 2.03 (s, 3 H, Ac)



HILIC-ELSD, $T_R = 15.09$ min



ESI-MS, calculated: 1769.6348; found [M+2H]²⁺ 885.8288



MALDI-MS, found [M-H]⁻ 1768.761

¹**H** NMR (D₂O, 500 MHz): δ 5.17 (d, J = 2.2 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.11 (s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.76 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.7 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.53-4.61 (m, 4 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1, Gal H-1), 4.24 (brs, 1 H), 4.18 (d, J = 1.9 Hz, 1 H), 4.09-4.12 (m, 2 H), 3.40-4.00 (m, 52 H), 2.75 (dd, J = 12.4, 4.7 Hz, 1 H, Neu5Ac H-3e), 2.07 (s, 3 H, Ac), 2.04 (2 s, 6 H, 2 Ac), 2.03 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 1.79 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 16.16$ min



ESI-MS, calculated: 1769.6348; found [M+2H]²⁺ 885.8287



MALDI-MS, found [M-H]⁻ 1768.553

¹**H** NMR (D₂O, 500 MHz): δ 5.20 (d, J = 2.3 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.15 (s, 1 H, Man2 H-1), 4.94 (s, 1 H, Man3 H-1), 4.76-4.85 (overlapped with D₂O, 1 H, Manβ H-1), 4.71 (d, J = 7.9 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.61-4.63 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.57 (d, J = 8.4 Hz, 1 H, GlcNAc-4 H-1), 4.46 (d, J = 7.9 Hz, 1 H, Gal H-1), 4.27 (brs, 1 H), 4.21-4.22 (m, 1 H), 4.11-4.13 (m, 1 H), 3.42-4.03 (m, 52 H), 2.68 (dd, J = 12.5, 4.7 Hz, 1 H, Neu5Ac H-3e), 2.09 (s, 3 H, Ac), 2.08 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 1.74 (t, J = 12.5 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 15.30$ min



ESI-MS, calculated: 1624.5973; found [M+2H]²⁺ 813.3104



MALDI-MS, found [M+Na]⁺ 1647.664

¹**H** NMR (D₂O, 500 MHz): δ 5.21 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.14 (d, J = 4.0 Hz, 1 H, Fuc H-1), 5.13 (s, 1 H, Man2 H-1), 4.94 (s, 1 H, Man3 H-1), 4.70-4.80 (overlapped with D₂O, 1 H, Manβ H-1), 4.56-4.62 (m, 3.4 H, GlcNAc-1 H-1 of β anomer, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.48 (d, J = 7.4 Hz, 1 H, Gal H-1), 4.27 (brs, 1 H), 4.20 (brs, 1 H), 4.13 (brs, 1 H), 3.45-4.01 (m, 49 H), 2.10 (s, 3 H, Ac), 2.06 (s, 9 H, 3 Ac), 1.19 (d, J = 6.0 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 16.71$ min



ESI-MS, calculated: 1915.6927; found [M+2H]²⁺ 958.8585



MALDI-MS, found [M-H]⁺ 1914.645

¹**H** NMR (D₂O, 500 MHz): δ 5.13 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.06 (d, J = 4.1 Hz, 1 H, Fuc H-1), 5.05 (s, 1 H, Man2 H-1), 4.87 (s, 1 H, Man3 H-1), 4.72 (s, 1 H, Manβ H-1), 4.64 (d, J = 7.3 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.49-4.56 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.46 (d, J = 7.7 Hz, 1 H, Gal H-1), 4.20 (brs, 1 H), 4.13-4.14 (m, 1 H), 4.02-4.05 (m, 2 H), 3.35-3.96 (m, 55 H), 2.71 (dd, J = 12.0, 4.0 Hz, 1 H, Neu5Ac H-3e), 2.06 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 2.00 (s, 6 H, 2 Ac), 1.99 (s, 3 H, Ac), 1.74 (t, J = 12.0 Hz, 1 H, Neu5Ac H-3a), 1.11 (t, J = 6.3 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 16.83$ min



ESI-MS, calculated: 1931.6876; found [M+2H]²⁺ 966.8554



MALDI-MS, found [M-H]- 1930.878

¹**H** NMR (D₂O, 500 MHz): δ5.14 (d, J = 1.4 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.07 (s, 1 H, Man2 H-1), 4.88 (s, 1 H, Man3 H-1), 4.72 (s, 1 H, Manβ H-1), 4.65 (d, J = 7.7 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.52-4.62 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.50 (d, J = 7.8 Hz, 1 H, Gal-1 H-1), 4.42 (d, J = 7.8 Hz, 1 H, Gal-2 H-1), 4.20 (brs, 1 H), 4.14 (d, J = 1.7 Hz, 1 H), 4.06-4.08 (m, 2 H), 3.41-3.95 (m, 57 H), 2.71 (dd, J = 12.3, 4.4 Hz, 1 H, Neu5Ac H-3e), 2.03 (s, 3 H, Ac), 2.00 (2 s, 3 H, 2 Ac), 1.99 (s, 3 H, Ac), 1.98 (s, 3 H, Ac), 1.75 (t, J = 12.3 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 17.85$ min



ESI-MS, calculated: 1931.6876; found [M+2H]²⁺ 966.8562



MALDI-MS, found [M-H]⁻ 1930.765

¹**H** NMR (D₂O, 500 MHz): δ 5.21 (d, J = 2.1 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.15 (s, 1 H, Man2 H-1), 4.95 (s, 1 H, Man3 H-1), 4.76-4.85 (overlapped with D₂O, 1 H, Manβ H-1), 4.72 (d, J = 7.5 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.59-4.64 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.49 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 4.46 (d, J = 7.9 Hz, 1 H, Gal-2 H-1), 4.28 (brs, 1 H), 4.21 (d, J = 1.9 Hz, 1 H), 4.13-4.14 (m, 1 H), 3.49-4.03 (m, 58 H), 2.68 (dd, J = 12.4, 4.6 Hz, 1 H, Neu5Ac H-3e), 2.10 (s, 3 H, Ac), 2.09 (s, 3 H, Ac), 2.07 (s, 3 H, Ac), 2.05 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 1.74 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a)


HILIC-ELSD, $T_R = 17.11$ min



ESI-MS, calculated: 1786.6501; found [M+2H]²⁺ 894.3378



MALDI-MS, found [M+Na]⁺ 1809.562

¹**H** NMR (D₂O, 500 MHz): δ 5.19 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.13 (d, J = 3.7 Hz, 1 H, Fuc H-1), 5.11 (s, 1 H, Man2 H-1), 4.93 (s, 1 H, Man3 H-1), 4.77 (s, 1 H, Manβ H-1), 4.70 (d, J = 7.7 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.57-4.62 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.48 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.45 (d, J = 7.9 Hz, 1 H, Gal-2 H-1), 4.24-4.25 (brs, 1 H), 4.19-4.20 (m, 1 H), 4.10-4.11 (m, 1 H), 3.47-4.03 (m, 55 H), 2.08 (s, 3 H, Ac), 2.05 (s, 9 H, 3 Ac), 1.17 (d, J = 6.4 Hz, 3 H, Fuc-CH₃)







ESI-MS, calculated: 2077.7455; found [M+2H]²⁺ 1039.8862



MALDI-MS, found [M-H]⁻ 2076.598

¹**H** NMR (D₂O, 500 MHz): δ 5.18 (d, J = 0.9 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.11 (d, J = 4.1 Hz, 1 H, Fuc H-1), 5.10 (s, 1 H, Man2 H-1), 4.93 (s, 1 H, Man3 H-1), 4.76 (s, 1 H, Manβ H-1), 4.69 (d, J = 7.7 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.57-4.62 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.50 (d, J = 7.8 Hz, 1 H, Gal-1 H-1), 4.47 (d, J = 7.8 Hz, 1 H, Gal-2 H-1), 4.25 (brs, 1 H), 4.18 (d, J = 1.7 Hz, 1 H), 4.07-4.11 (m, 2 H), 3.46-4.01 (m, 61 H), 2.76 (dd, J = 12.5, 4.6 Hz, 1 H, Neu5Ac H-3e), 2.08 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.03 (2 s, 6 H, 2 Ac), 2.02 (s, 3 H, Ac), 1.79 (t, J = 12.5 Hz, 1 H, Neu5Ac H-3a), 1.16 (d, J = 6.5 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 19.25$ min



ESI-MS, calculated: 2222.7830; found [M+2H]²⁺ 1112.4035



¹**H** NMR (D₂O, 500 MHz): δ 5.17 (d, J = 2.6 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.10 (s, 1 H, Man2 H-1), 4.93 (s, 1 H, Man3 H-1), 4.76 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.9 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.53-4.58 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.53 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 4.43 (d, J = 7.9 Hz, 1 H, Gal-2 H-1), 4.24 (brs, 1 H), 4.15 (m, 1 H), 4.09-4.11 (m, 2 H), 3.47-4.00 (m, 64 H), 2.74 (dd, J = 12.7, 4.8 Hz, 1 H, Neu5NAc-1 H-3e), 2.64 (dd, J = 12.5, 4.6 Hz, 1 H, Neu5NAc-2 H-3e), 2.05 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.01 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 6 H, 2 Ac), 1.76 (t, J = 12.7 Hz, 1 H, Neu5NAc-1 H-3a), 1.69 (dd, J = 12.5 Hz, Neu5NAc-2 H-3a).



HILIC-ELSD, $T_R = 18.27$ min



ESI-MS, calculated: 2077.7455; found [M+2H]²⁺ 1039.8886



MALDI-MS, found [M-H]⁻ 2076.858

¹**H NMR** (D₂O, 500 MHz): δ 5.22 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.16 (d, J = 3.3 Hz, 1 H, Fuc H-1), 5.13 (s, 1 H, Man2 H-1), 4.96 (s, 1 H, Man3 H-1), 4.70-4.90 (overlapped with D₂O, 1 H, Manβ H-1), 4.58-4.62 (m, 4.4 H, GlcNAc-1 H-1 of β anomer, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1, Gal-1 H-1), 4.48 (d, J = 7.7 Hz, 1 H, Gal-2 H-1), 4.28 (brs, 1 H), 4.22 (brs, 1 H), 4.13-4.15 (m, 2 H), 3.47-4.03 (m, 61 H), 2.79 (dd, J = 12.0, 3.4 Hz, 1 H, Neu5Ac H-3e), 2.11 (s, 3 H, Ac), 2.07 (s, 12 H, 4 Ac), 1.83 (t, J = 12.0 Hz, 1 H, Neu5Ac H-3a), 1.20 (d, J = 6.0 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 19.75$ min



ESI-MS, calculated: 2368.8409; found [M+2H]²⁺ 1185.9312



¹**H** NMR (D₂O, 500 MHz): δ 5.15 (d, J = 2.1 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.08 (d, J = 4.0 Hz, 1 H, Fuc H-1), 5.07 (s, 1 H, Man2 H-1), 4.89 (s, 1 H, Man3 H-1), 4.73 (s, 1 H, Manβ H-1), 4.66 (d, J = 7.7 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.51-4.58 (m, 4 H, GlcNAc-2 H-1, GlcNAc-4 H-1, Gal-1 H-1), 4.48 (d, J = 7.8 Hz, 1 H, Gal-2 H-1), 4.22 (brs, 1 H), 4.15-4.16 (m, 1 H), 4.04-4.10 (m, 3 H), 3.43-3.98 (m, 67 H), 2.71-2.74 (m, 2 H, Neu5Ac H-3e), 2.05 (s, 3 H, Ac), 2.01 (s, 6 H, 2 Ac), 2.00 (s, 9 H, 3 Ac), 1.77 (t, J = 12.0 Hz, 1 H, Neu5Ac H-3a), 1.76 (t, J = 12.0 Hz, Neu5Ac-2 H-3a), 1.13 (t, J = 6.5 Hz, 3 H, Fuc-CH₃)





ESI-MS, calculated: 2077.7455; found [M+2H]²⁺ 1039.8842



MALDI-MS, found [M-H]⁻ 2076.549

¹**H** NMR (D₂O, 500 MHz): δ 5.14 (d, J = 2.5 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.08 (d, J = 3.9 Hz, 1 H, Fuc H-1), 5.06 (s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.73 (s, 1 H, Manβ H-1), 4.65 (d, J = 7.8 Hz, 0.5 H, GlcNAc-1 H1 of β anomer), 4.53-4.57 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.41 (d, J = 7.9 Hz, 1 H, Gal-1 H-1), 4.40 (d, J = 7.7 Hz, 1 H, Gal-2 H-1), 4.21 (s, 1 H), 4.14 (d, J = 2.2 Hz, 1 H), 4.07 (d, J = 2.9 Hz, 1 H), 3.41-3.97 (m, 62 H), 2.63 (dd, J = 12.4, 4.7 Hz, 1 H, Neu5Ac H-3e), 2.04 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 3 H, Ac), 1.98 (s, 3 H, Ac), 1.68 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a), 1.13 (s, 3 H, Fuc-CH₃);







ESI-MS, calculated: 2368.8409; found [M+2H]²⁺ 1185.9282



ESI-MS, found $[M+2H]^{2+}$

¹**H** NMR (D₂O, 500 MHz): δ5.15 (d, J = 2.2 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.08 (d, J = 3.8 Hz, 1 H, Fuc H-1), 5.07 (s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.74 (s, 1 H, Manβ H-1), 4.66 (d, J = 7.6 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.53-4.58 (m, 3 H, GlcNAc-2 H-1, GlcNAc-2 H-1, GlcNAc-4 H-1), 4.48 (d, J = 7.7 Hz, 1 H, Gal-1 H-1), 4.41 (d, J = 7.8 Hz, 1 H, Gal-2 H-1), 4.22 (brs, 1 H), 4.15 (d, J = 2.1 Hz, 1 H), 4.08 (d, J = 1.3 Hz, 1 H), 4.05 (dd, J = 9.7, 2.7 Hz, 1 H), 3.43-3.98 (m, 68 H), 2.73 (dd, J = 12.2, 4.3 Hz, 1 H, Neu5Ac-1 H-3e), 2.64 (dd, J = 12.4, 4.6 Hz, 1 H, Neu5Ac-2 H-1), 2.05 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 6 H), 1.76 (t, J = 12.2 Hz, 1 H, Neu5Ac-1 H-3a), 1.69 (t, J = 12.4 Hz, Neu5Ac-2 H-3a), 1.13 (t, J = 6.5 Hz, 3 H, Fuc-CH₃)







ESI-MS, calculated: 2223.8034; found [M+2H]²⁺ 1112.9150



MALDI-MS, found [M-H]⁻ 2222.648

¹**H NMR** (D₂O, 500 MHz): δ5.18 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.10-5.12 (m, 3 H, Fuc-1 H-1. Fuc-2 H-1, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.76 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.6 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.55-4.62 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.50 (d, J = 6.8 Hz, 1 H, Gal H-1), 4.44 (d, J = 8.0 Hz, 1 H, Gal-2 H-1), 4.24 (brs, 1 H), 4.18 (brs, 1 H), 4.06-4.10 (m, 3 H), 3.45-4.03 (m, 64 H), 2.75 (dd, J = 12.4, 4.0 Hz, 1 H, Neu5Ac H-3e), 2.07 (s, 3 H, Ac), 2.03 (s, 12 H, 4 Ac), 1.79 (t, J = 12.4 Hz, 1 H, Neu5Ac-H3a), 1.13-2.21 (m, 6 H, Fuc-1 CH₃, Fuc-2 CH₃)



HILIC-ELSD, $T_R = 5.88 \text{ min}$



ESI-MS, calculated: 1442.5182; found [M+2H]²⁺ 722.2684

MALDI-MS, found [M+Na]⁺ 1465.573, [M+K]⁺ 1481.534



NMR data listed in Part VI



HILIC-ELSD, $T_R = 13.43$ min



ESI-MS, calculated: 1478.5393; found [M+2H]²⁺ 740.2793



MALDI-MS, found [M+Na]⁺ 1501.587, [M+K]⁺ 1517.677

¹**H NMR** (D₂O, 500 MHz): δ 5.17 (d, J = 2.0 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.10 (s, 1 H, Man2 H-1), 4.92 (s, 1 H, Man3 H-1), 4.75 (s, 1 H, Manβ H-1), 4.68 (d, J = 7.8 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.60 (d, J = 7.8 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.59 (d, J = 7.8 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.57 (d, J = 8.3 Hz, 1 H, GlcNAc-3 H-1), 4.54 (d, J = 8.4 Hz, 1 H, GlcNAc-4 H-1), 4.46 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.24 (d, J = 2.2 Hz, 1 H), 4.17 (d, J = 1.9 Hz, 1 H), 4.10 (d, J = 2.1 Hz, 1 H), 3.40-3.98 (m, 45 H), 2.07 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.02 (s, 3 H, Ac)



HILIC-ELSD, $T_R = 14.81$ min



ESI-MS, calculated: 1769.6348; found [M+2H]²⁺ 885.8268



MALDI-MS, found [M-H]⁻ 1768.546

¹**H NMR** (D₂O, 500 MHz): δ 5.14 (d, J = 2.3 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.07 (s, 1 H, Man2 H-1), 4.88 (s, 1 H, Man3 H-1), 4.72 (s, 1 H, Manβ H-1), 4.65 (d, J = 8.0 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.50-4.57 (m, 4 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1, Gal H-1), 4.20 (d, J = 2.1 Hz, 1 H), 4.14 (d, J = 2.3 Hz, 1 H), 4.07-4.09 (m, 2 H), 3.40-3.96 (m, 51 H), 2.71 (dd, J = 12.4, 4.5 Hz, 1 H, Neu5Ac H-3e), 2.04 (s, 3 H, Ac), 2.01 (s, 3 H, Ac), 2.00 (2 s, 6 H, 2 Ac), 1.99 (s, 3 H, 2 Ac), 1.76 (d, J = 12.4 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 15.84$ min



ESI-MS, calculated: 1769.6348; found [M+2H]²⁺ 885.8272



MALDI-MS, found [M-H]⁻ 1768.684

¹**H** NMR (D₂O, 500 MHz): δ 5.14 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.07 (s, 1 H, Man2 H-1), 4.90 (s, 1 H, Man3 H-1), 4.73 (s, 1 H, Manβ H-1), 4.65 (d, J = 7.3 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.54-4.56 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.50 (d, J = 8.4 Hz, 1 H, GlcNAc-4 H-1), 4.40 (d, J = 8.0 Hz, 1 H, Gal H-1), 4.21 (s, 1 H), 4.14 (brs, 1 H), 4.07 (brs, 1 H), 3.38-3.96 (m, 52 H), 2.62 (dd, J = 12.4, 4.5 Hz, 1 H, Neu5Ac H-3e), 2.04 (s, 3 H, Ac), 2.02 (s, 3 H, Ac), 2.01 (s, 3 H, Ac), 1.99 (s, 3 H, Ac), 1.98 (s, 3 H, Ac), 1.68 (d, J = 12.4 Hz, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 15.31$ min



ESI-MS, calculated: 1624.5973; found [M+2H]²⁺ 813.3076



MALDI-MS, found [M+Na]⁺ 1647.775, [M+K]⁺ 1663.773

¹**H** NMR (D₂O, 500 MHz): δ 5.13 (d, J = 2.2 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.07 (d, J = 3.9 Hz, 1 H, Fuc H-1), 5.06 (s, 1 H, Man2 H-1), 4.86 (s, 1 H, Man3 H-1), 4.72 (s, 1 H, Manβ H-1), 4.64 (d, J = 7.8 Hz, 0.4 H, GlcNAc-1H1 of β anomer), 4.52-4.56 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.49 (d, J = 8.5 Hz, 1 H, GlcNAc-4 H-1), 4.39 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.20 (s, 1 H), 4.13 (d, J = 1.8 Hz, 1 H), 4.04 (d, J = 1.6 Hz, 1 H), 3.37-3.95 (m, 49 H), 2.03 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.98 (s, 6 H, 2 Ac), 1.12 (d, J = 6.6 Hz, Fuc-CH₃)



HILIC-ELSD, $T_R = 16.65$ min



ESI-MS, calculated: 1915.6927; found [M+2H]²⁺ 958.8521



MALDI-MS, found [M-H]⁺ 1914.547

¹**H** NMR (D₂O, 500 MHz): δ 5.14 (d, J = 2.4 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.08 (d, J = 4.0 Hz, 1 H, Fuc H-1), 5.06 (s, 1 H, Man2 H-1), 4.87 (s, 1 H, Man3 H-1), 4.73 (s, 1 H. Manβ H-1), 4.65 (d, J = 7.8 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.52-4.57 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.50 (d, J = 8.4 Hz, 1 H, GlcNAc-4 H-1), 4.47 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.21 (s, 1 H), 4.14 (d, J = 2.5 Hz, 1 H), 4.03-4.06 (m, 2 H), 3.37-3.97 (m, 55 H), 2.72 (dd, J = 12.6, 4.7 Hz, 1 H, Neu5Ac H-3e), 2.04 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 6 H, 2 Ac), 1.98 (s, 3 H, Ac), 1.75 (t, J = 12.6 Hz, 1 H, Neu5Ac H-3a), 1.12 (d, J = 6.5 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 16.72 \text{ min}$



ESI-MS, calculated: 1931.6876; found [M+2H]²⁺ 966.8540



MALDI-MS, found [M-H]- 1930.604

¹**H** NMR (D₂O, 500 MHz): δ 5.13 (d, J = 1.8 Hz, 0.6 H, GlcNAc-1 H1 of α anomer), 5.07 (s, 1 H, Man2 H-1), 4.88 (s, 1 H, Man3 H-1), 4.71 (s, 1 H, Manβ H-1), 4.64 (d, J = 7.6 Hz, 0.4 H, GlcNAc-1 H1 of β anomer), 4.49-4.57 (m, 4 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1, Gal-1 H-1), 4.41 (d, J = 7.9 Hz, 1 H, Gal-2 H-1), 4.20 (brs, 1 H), 4.14 (d, J = 1.6 Hz, 1 H), 4.05-4.08 (m, 2 H), 3.41-3.95 (m, 51 H), 2.71 (dd, J = 12.2, 4.2 Hz, 1 H, Neu5Ac H3e), 2.03 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 6 H, 2 Ac), 1.98 (s, 3 H, Ac), 1.75 (t, J = 12.2, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 17.88$ min



ESI-MS, calculated: 1931.6876; found [M+2H]²⁺ 966.8527



MALDI-MS, found [M-H]⁻ 1930.520

¹**H NMR** (D₂O, 500 MHz): δ 5.19 (d, J = 2.3 Hz, 0.6 H, GlcNAc-1 H1 of α anomer), 5.12 (s, 1 H, Man2 H-1), 4.95 (s, 1 H, Man3 H-1), 4.81 (s, 1 H, Manβ H-1), 4.69 (d, J = 8.0 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.57-4.62 (m, 3 H, GlcNAc-2 H-1, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.47 (d, J = 8.0 Hz, 1 H, Gal-1 H-1), 4.45 (d, J = 8.3 Hz, 1 H, Gal-2 H-1), 4.26 (s, 1 H), 4.19 (d, J = 2.2 Hz, 1 H), 4.12 (d, J = 1.7 Hz, 1 H), 3.45-4.01 (m, 58 H), 2.67 (dd, J = 12.4, 4.6 Hz, 1 H, Neu5Ac H-3e), 2.08 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 1.72 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a)



HILIC-ELSD, $T_R = 17.35$ min



ESI-MS, calculated: 1786.6501; found [M+2H]²⁺ 894.3334



MALDI-MS, found [M+Na]⁺ 1809.776, [M+K]⁺ 1825.755

¹**H** NMR (D₂O, 500 MHz): δ 5.15 (d, J = 2.0 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.10 (d, J = 4.0 Hz, 1 H, Fuc H-1), 5.08 (s, 1 H, Man2 H-1), 4.88 (s, 1 H, Man3 H-1), 4.74 (Manβ H-1), 4.66 (d, J = 7.6 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.54-4.59 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.43 (d, J = 8.2 Hz, 1 H, Gal-1 H-1), 4.41 (d, J = 8.3 Hz, 1 H, Gal-2 H-1), 4.22 (s, 1 H), 4.16 (d, J = 2.7 Hz, 1 H), 4.07 (d, J = 2.5 Hz, 1 H), 3.42-3.98 (m, 55 H), 2.05 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.00 (s, 6 H, 2 Ac), 1.15 (d, J = 6.6 Hz, 3 H, Fuc-CH₃)



mV 1.5 1.0 0.5 0.0 0.0 5.0 10.0 15.0 20.0 25.0 min

HILIC-ELSD, $T_R = 18.56$ min

ESI-MS, calculated: 2077.7455; found [M+2H]²⁺ 1039.8843



MALDI-MS, found [M-H]⁻ 2076.737

¹**H** NMR (D₂O, 500 MHz): δ5.12 (d, J = 1.6 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.05-5.06 (d, J = 4.4 Hz, 1 H, Fuc H-1), 5.05 (s, 1 H, Man2 H-1), 4.85 (s, 1 H, Man3 H-1), 4.71 (s, 1 H, Manβ H-1), 4.63 (d, J = 7.6 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.50-4.55 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.46 (d, J = 7.8 Hz, 1 H, Gal-1 H-1), 4.40 (d, J = 7.8 Hz, 1 H, Gal-2 H-1), 4.19 (brs, 1 H), 4.13 (brs, 1 H), 4.01-4.05 (m, 2 H), 3.8-3.96 (m, 61 H), 2.70 (dd, J = 12.2, 4.2 Hz, 1 H, Neu5Ac H-3e), 2.02 (s, 3 H, Ac), 1.99 (s, 3 H, Ac), 1.97 (s, 6 H, 2 Ac), 1.96 (s, 3 H, Ac), 1.73 (t, J = 12.2 Hz, 1 H, Neu5Ac H-3a), 1.11 (d, J = 6.5 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 19.24$ min



ESI-MS, calculated: 2222.7830; found [M+2H]²⁺ 1112.4033



¹**H** NMR (D₂O, 500 MHz): δ 5.15 (d, J = 2.3 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.08 (s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.74 (s, 1 H, Manβ H-1), 4.66 (d, J = 7.5 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.53-4.58 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.51 (d, J = 7.8 Hz, 1 H, Gal-1 H-1), 4.41 (d, J = 7.8 Hz, 1 H, Gal-2 H-1), 4.22 (brs, 1 H), 4.15 (d, J = 2.1 Hz, 1 H), 4.06-4.09 (m, 2 H), 3.45-3.98 (m, 64 H), 2.72 (dd, J = 12.7, 4.7 Hz, 1 H, Neu5NAc-1 H-3e), 2.64 (dd, J = 12.5, 4.8 Hz, 1 H, Neu5NAc-2 H-3e), 2.05 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.01 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 6 H, 2 Ac), 1.76 (t, J = 11.5 Hz, 1 H, Neu5NAc-1 H-3a), 1.69 (dd, J = 12.7 Hz, Neu5NAc-2 H-3a)



HILIC-ELSD, $T_R = 18.48$ min



ESI-MS, calculated: 2077.7455; found [M+2H]²⁺ 1039.8843



MALDI-MS, found [M-H]⁻ 2076.656

¹**H** NMR (D₂O, 500 MHz): δ 5.12 (d, J = 2.1 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.07 (d, J = 3.9 Hz, 1 H, Fuc H-1), 5.05 (s, 1 H, Man2 H-1), 4.85 (s, 1 H, Man3 H-1), 4.71 (s, 1 H, Manβ H-1), 4.63 (d, J = 7.0 Hz, 0.5 H, GlcNAc-1 H1 of β anomer), 4.47-4.55 (m, 4 H, GlcNAc-2 H-1, GlcNAC-3 H-1, GlcNAc-4 H-1,Gal-1 H-1), 4.38 (d, J = 7.7 Hz, 1 H, Gal-2 H-1), 4.19 (s, 1 H), 4.12 (d, J = 3.0 Hz, 1 H), 4.03-4.06 (m, 2 H), 3.38-3.97 (m, 61 H), 2.69 (dd, J = 12.4, 4.4 Hz, 1 H, Neu5Ac H-3e), 2.02 (s, 3 H, Ac), 1.98 (s, 3 H, Ac), 1.97 (s, 6 H, 2 Ac), 1.96 (s, 3 H, Ac), 1.73 (t, J = 12.4 Hz, 1 H, Neu5Ac H-3a), 1.11 (d, J = 6.6 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 19.79$ min



ESI-MS, calculated: 2368.8409; found [M+2H]²⁺ 1185.9313



ESI-MS, found $[M+2H]^{2+}$

¹**H** NMR (D₂O, 500 MHz): δ 5.07-5.09 (m, 2 H), 4.87 (s, 1 H, Man2 H-1), 4.80 (overlapped with D₂O, 1 H, Man3 H-1), 4.73 (s, 1 H, Manβ H-1), 4.46-4.56 (m, 5 H), 4.21 (brs, 1H), 4.14 (d, J = 2.2 Hz, 1 H), 4.03-4.07 (m, 3 H), 3.40-4.00 (m, 67 H), 2.68-2.74 (m, 2 H, Neu5Ac H-3e), 2.04 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 6 H, 2 Ac), 1.98 (s, 6 H, 2 Ac), 1.76 (t, J = 12.0 Hz, 2 H, Neu5Ac H-3a), 1.13 (d, J = 6.2 Hz, 3 H, Fuc-CH₃)





ESI-MS, calculated: 2077.7455; found [M+2H]²⁺ 1039.8862



MALDI-MS, found [M-H]⁻ 2076.744

¹**H** NMR (D₂O, 500 MHz): δ 5.15 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.08-5.10 (m, 2 H, Fuc H-1, Man2 H-1), 4.89 (s, 1 H, Man3 H-1), 4.74 (s, 1 H, Manβ H-1), 4.65 (d, J = 7.7 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.54-4.57 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.40 (d, J = 7.5 Hz, 2 H, Gal-1 H-1, Gal-2 H-1), 4.22 (brs, 1 H), 4.16 (brs, 1 H), 4.06 (brs, 1 H), 3.41-3.97 (m, 63 H), 2.63 (dd, J = 12.5, 4.9 Hz, 1 H, Neu5Ac H-3e), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 2.00 (s, 6 H, 2 Ac), 1.99 (s, 3 H, Ac), 1.68 (t, J = 12.5 Hz, 1 H, Neu5Ac), 1.14 (d, J = 6.4 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 20.82$ min



ESI-MS, calculated: 2368.8409; found [M+2H]²⁺ 1185.9309



¹**H** NMR (D₂O, 500 MHz): δ 5.14 (d, J = 2.6 Hz, 0.4 H, GlcNAc-1 H-1 of α anomer), 5.09 (s, 1 H, Man2 H-1), 5.08 (d, J = 3.9 Hz, 1 H, Fuc H-1), 4.87 (s, 1 H, Man3 H-1), 4.73 (s, 1 H, Manβ H-1), 4.65 (d, J = 7.8 Hz, 0.6 H, GlcNAc-1 H-1 of β anomer), 4.52-4.57 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3, GlcNAc-4), 4.48 (d, J = 7.6 Hz, 1 H, Gal-1 H-1), 4.40 (d, J = 7.9 Hz, 1 H, Gal-2 H-1), 4.22 (s, 1 H), 4.15 (d, J = 3.1 Hz, 1 H), 4.03-4.06 (m, 2 H), 3.40-3.97 (m, 68 H), 2.72 (dd, J = 12.2, 4.4 Hz, 1 H, Neu5Ac-1 H-3e), 2.62 (dd, J = 12.8, 4.8 Hz, 1 H, Neu5Ac-2 H-3e), 2.04 (s, 3 H, Ac), 2.03 (s, 3 H, Ac), 1.99 (s, 6 H, 2 Ac), 1.98 (s, 6 H, 2 Ac), 1.75 (t, J = 12.2 Hz, 1 H, Neu5Ac-1 H-3a), 1.68 (t, J = 12.8 Hz, 1 H, Neu5Ac-2 H-3a), 1.13 (d, J = 6.2 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 20.18$ min



ESI-MS, calculated: 2223.8034; found [M+2H]²⁺ 1112.9105



MALDI-MS, found [M-H]⁻ 2222.841

¹**H** NMR (D₂O, 500 MHz): δ 5.14 (d, J = 2.3 Hz, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.08 (d, J = 3.9 Hz, 2 H, Fuc-1 H-1, Fuc-2 H-1), 5.06 (s, 1 H, Man2 H-1), 4.87 (s, 1 H, Man3 H-1), 4.73 (s, 1 H, Manβ H-1), 4.65 (d, J = 8.2 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.53-4.57 (m, 3 H, GlcNAc-2 H-1, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.47 (d, J = 7.8 Hz, 1 H, Gal-1 H-1), 4.39 (d, J = 7.8 Hz, 1 H, Gal-2 H-1), 4.21 (s, 1 H), 4.14 (d, J = 2.3 Hz, 1 H), 4.03-4.07 (m, 2 H), 3.40-3.96 (m, 65 H), 2.72 (dd, J = 12.2, 4.7 Hz, 1 H, Neu5Ac H-3e), 2.04 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 6 H, 2 Ac), 1.98 (s, 3 H, Ac), 1.75 (t, J = 12.2 Hz, 1 H, Neu5Ac H-3a), 1.13 (d, J = 6.6 Hz, 6 H, Fuc-1 CH₃, Fuc-2 CH₃)



HILIC-ELSD, $T_R = 19.13$ min

0.25 0.25 0.00 0.0 5.0 10.0 15.0 20.0 25.0 min

ESI-MS, calculated: 1906.6560; found [M+2H]²⁺ 954.3400



MALDI-MS, found [M-H]⁻ 1905.612

¹**H** NMR (D₂O, 500 MHz): δ5.20 (s, 1 H, Man5 H-1), 5.14 (d, J = 1.3 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.07 (s, 1 H, Man2 H-1), 4.90 (s, 1 H, Man3 H-1), 4.85 (s, 1 H, Man4 H-1), 4.74-4.83 (overlapped with D₂O, 1 H, Manβ H-1), 4.65 (d, J = 7.7 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.57 (d, J = 7.7 Hz, 0.6 H, GlcNAc-2 H-1 of α anomer), 4.56 (d, J = 7.7 Hz, 0.4 H, GlcNAc-2 H-1 of β anomer), 4.53 (d, J = 6.8 Hz, 1 H, GlcNAc-2 H-1), 4.50 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.20 (d, J = 1.0 Hz, 1 H), 4.16 (d, J = 1.2 Hz, 1 H), 4.07-4.09 (m, 3 H), 3.43-4.01 (m, 58 H), 2.73 (dd, J = 12.3, 4.5 Hz, 1 H, Neu5Gc H-3e), 2.03 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 3 H, Ac), 1.77 (t, J = 12.3 Hz, 1 H, Neu5Gc H-3a)





ESI-MS, calculated: 1906.6560; found [M+2H]²⁺ 954.3416



MALDI-MS, found [M-H]⁻ 1905.505

¹**H NMR** (D₂O, 500 MHz): δ 5.18 (s, 1 H, Man5 H-1), 5.13 (brs, 0.5 H, GlcNAc-1 H-1 of α anomer), 5.06 (s, 1 H, Man2 H-1), 4.88 (s, 1 H, Man3 H-1), 4.83 (s, 1 H, Man4 H-1), 4.75-4.80 (overlapped with D₂O, 1 H, Manβ H-1), 4.63 (d, J = 6.2 Hz, 0.5 H, GlcNAc-1 H-1 of β anomer), 4.53-4.56 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.38 (d, J = 7.7 Hz, 1 H, Gal H-1), 4.19 (brs, 1 H), 4.15 (brs, 1 H), 4.05 (brs, 1 H), 3.43-3.99 (m, 59 H), 2.62 (dd, J = 12.5, 3.9 Hz, 1 H, Neu5Gc H-3e), 2.01 (s, 6 H, 2 Ac), 1.98 (s, 3 H, Ac), 1.68 (t, J = 12.5 Hz, 1 H, Neu5Gc H-3a)



HILIC-ELSD, $T_R = 20.66$ min



ESI-MS, calculated: 2052.7139; found [M+2H]²⁺ 1027.3722



MALDI-MS, found [M-H]⁻ 2051.569

¹**H** NMR (D₂O, 500 MHz): δ 5.20 (s, 1 H, Man5 H-1), 5.15 (brs, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.08 (d, J = 3.5 Hz, 1 H, Fuc H-1), 5.06 (s, 1 H, Man2 H-1), 4.91 (s, 1 H, Man3 H-1), 4.86 (s, 1 H, Man4 H-1), 4.75-4.83 (overlapped with D₂O, 1 H, Manβ H-1), 4.65 (d, J = 6.4 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.53-4.58 (m, 2 H, GlcNAc-2 H-1, GlcNAc-3 H-1), 4.47 (d, J = 7.7 Hz, 1 H, Gal H-1), 4.21 (brs, 1 H), 4.15-4.16 (m, 1 H), 4.05-4.08 (m, 3 H), 3.42-4.01 (m, 62 H), 2.74 (dd, J = 12.4, 4.8 Hz, 1 H, Neu5Gc H-3e), 2.04 (s, 3 H, Ac), 2.00 (s, 6 H, 2 Ac), 1.77 (t, J = 12.4 Hz, 1 H, Neu5Gc H-3a), 1.13 (t, J = 6.0 Hz, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 12.11$ min



ESI-MS, calculated: 1462.5444; found [M+2H]²⁺ 732.2835



MALDI-MS, found [M+Na]⁺ 1485.345

¹**H** NMR (D₂O, 500 MHz): δ 5.20 (d, J = 3.0 Hz, 0.4 H, GlcNAc-1 H-1 of α anomer), 5.13 (s, 1 H, Man2 H-1), 4.93 (s, 1 H, Man3 H-1), 4.91 (d, 0.4 H, J = 3.6 Hz, Fuc H-1 of a anomer), 4.90 (d, 0.6 H, J = 3.6 Hz, Fuc H-1 of β anomer), 4.75-4.85 (overlapped with D₂O, 1 H, Manβ H-1), 4.71 (d, J = 8.0 Hz, 0.6 H, GlcNAc-1 H-1 of β anomer), 4.69 (d, J = 8.1 Hz, 0.4 H, GlcNAc-2 H-1 of α anomer), 4.68 (d, J = 7.7 Hz, 0.6 H, GlcNAc-1 H-1 of β anomer), 4.57 (d, J = 8.4 Hz, 2 H, GlcNAc-3 H-1, GlcNAc-4 H-1), 4.27 (brs, 1 H), 4.20 (d, J = 1.8 Hz, 1 H), 4.10 (m, 2 H), 3.43-4.02 (m, 42 H), 2.11 (s, 3 H, Ac), 2.07 (s, 6 H, 2 Ac), 2.06 (s, 3 H, Ac), 1.24 (d, 1.2 H, J = 5.1 Hz, Fuc-CH₃), 1.23 (d, 1.8 H, J = 6.4 Hz, Fuc-CH₃)



HILIC-ELSD, $T_R = 11.25$ min



ESI-MS, calculated: 1259.4651; found [M+2H]²⁺ 630.7428



MALDI-MS, found [M+Na]⁺ 1282.289, [M+K]⁺ 1298.266

¹**H NMR** (D₂O, 500 MHz): δ 5.18 (d, J = 2.9 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.12 (s, 1 H, Man2 H-1), 4.92 (s, 1 H, Man3 H-1), 4.88-4.90 (m, 1 H, Fuc H-1), 4.77-4.83 (overlapped with D₂O, 1 H, Manβ H-1), 4.69 (d, J = 8.1 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.67 (d, J = 8.1 Hz, 0.6 H, GlcNAc-2 H-1 of β anomer), 4.66 (d, J = 7.6 Hz, 0.4 H, GlcNAc-2 H-1 of α anomer), 4.55 (d, J = 8.4 Hz, 1 H, GlcNAc-3 H-1), 4.26 (brs, 1 H), 4.17-4.19 (m, 1 H), 4.07-4.13 (m, 1 H), 3.43-4.02 (m, 37 H), 2.09 (s, 3 H, Ac), 2.06 (s, 3 H, Ac), 2.04 (s, 3 H, Ac), 1.20-1.23 (m, 3 H, Fuc-CH₃)



HILIC-ELSD, $T_R = 13.87$ min



ESI-MS, calculated: 1624.5973; found [M+2H]²⁺ 813.3106



MALDI-MS, found [M+Na]⁺ 1647.470

¹**H NMR** (D₂O, 500 MHz): δ 5.14 (d, J = 3.0 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.07 (s, 1 H, Man2 H-1), 4.89 (s, 1 H, Man3 H-1), 4.85-4.86 (m, 1 H, Fuc H-1), 4.73 (s, 1 H, Manβ H-1), 4.65 (d, J = 8.1 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.61-4.64 (m, 1 H, GlcNAc-2 H-1), 4.54 (d, J = 8.2 Hz, 1 H, GlcNAc-3 H-1), 4.51 (d, J = 8. 4 Hz, 1 H, GlcNAc-4 H-1), 4.43 (d, J = 7.8 Hz, 1 H, Gal H-1), 4.21 (d, J = 1.4 Hz, 1 H), 4.13-4.15 (m, 1 H), 4.05-4.10 (m, 2 H), 3.40-3.98 (m, 48 H), 2.05 (s, 3 H, Ac), 2.01 (2 s, 6 H, 2 Ac), 2.00 (s, 3 H, Ac), 1.16-1.19 (m, 3 H, Fuc-CH₃)





ESI-MS, calculated: 1915.6927; found [M+2H]²⁺ 958.8591



MALDI-MS, found [M-H]⁻ 1914.803

¹**H** NMR (D₂O, 500 MHz): δ 5.13 (d, J = 2.5 Hz, 0.6 H, GlcNAc-1 H-1 of α anomer), 5.06 (s, 1 H, Man2 H-1), 4.87 (s, 1 H, Man3 H-1), 4.75-4.85 (overlapped with D₂O, 1 H, Fuc H-1), 4.72 (s, 1 H, Manβ H-1), 4.64 (d, J = 8.2 Hz, 0.4 H, GlcNAc-1 H-1 of β anomer), 4.60-4.62 (m, 1 H, GlcNAc-2 H-1), 4.49-4.53 (m, 3 H, GlcNAc-3 H-1, GlcNAc-4 H-1, Gal H-1), 4.20 (brs, 1 H), 4.13-4.14 (m, 1 H), 4.05-4.08 (m, 3 H), 3.38-3.95 (m, 54 H), 2.71 (dd, J = 12.5, 4.9 Hz, 1 H, Neu5Ac H-3e), 2.05 (s, 3 H, Ac), 2.00 (s, 3 H, Ac), 1.99 (s, 6 H, 2 Ac), 1.98 (s, 3 H, Ac), 1.75 (t, J = 12.5 Hz, 1 H, Neu5Ac H-3a), 1.17 (t, J = 5.6 Hz, 3 H, Fuc-CH₃)

VIII. NMR spectra of purified N-glycans







¹H NMR of **N010**











¹H NMR of **N012**



¹H NMR of **N015**
















¹H NMR of **N023**





























S115







7.0

6.5

6.0

5.0

4.5

5.5

4.0

з.о

3.5 f1 (ppm)

2.5

2.0

1.5

1.0

0.5



0.0













7.0

6.5

6.0



3.5 3.0 f1 (ppm)

2.5

2.0

1.5

1.0

0.5



5.0

4.5

4.0

5.5



0.0













































7.0

6.5

6.0

5.5

5.0

4.5

4.0 3.5 f1 (ppm) з.о

2.5

2.0

1.5

1.0



o.c

0.5















¹H NMR of **N015G**









¹H NMR of **N6211**





IX. References

- 1. G. Sugiarto, K. Lau, Y. Li, Z. Khedri, H. Yu, D. T. Le and X. Chen, *Mol. Biosyst.*, 2011, **7**, 3021.
- 2. H. Yu, S. Huang, H. Chokhawala, M. Sun, H. Zheng and X. Chen, *Angew. Chem. Int. Ed. Engl.*, 2006, **45**, 3938.
- 3. S. W. Lin, T. M. Yuan, J. R. Li and C. H. Lin, *Biochemistry*, 2006, **45**, 8108.
- 4. H. Yu, H. Yu, R. Karpel and X. Chen, *Bioorg. Med. Chem.*, 2004, **12**, 6427.
- 5. M. M. Muthana, J. Qu, Y. Li, L. Zhang, H. Yu, L. Ding, H. Malekan and X. Chen, *Chem. Commun.*, 2012, **48**, 2728.
- 6. G. Zhao, W. Guan, L. Cai and P. G. Wang, *Nat. Protoc.*, 2010, **5**, 636.
- 7. H. Paulsen, M. Heume and H. Nürnberger, *Carbohydr. Res.*, 1990, **200**, 127.
- 8. Y. Liu, Y. M. Chan, J. Wu, C. Chen, A. Benesi, J. Hu, Y. Wang and G. Chen, *Chembiochem*, 2011, **12**, 685.